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ABSTRACT 
 
Essential thrombocythaemia (ET) is a myeloproliferative disease (MPD) characterized by 
thrombocytosis, i.e. a constant elevation of platelet count. Thrombocytosis may appear in all MPDs 
(ET, polycythaemia vera, chronic myeloid leukaemia, and myelofibrosis) and as a reactive 
phenomenon in a variety of disorders. The differential diagnosis of thrombocytosis is important, 
because the clinical course, need of therapy, and prognosis are different in patients with MPDs and 
in those with reactive thrombocytosis. ET patients may remain asymptomatic for years, but serious 
thrombohaemorrhagic and pregnancy-related complications may occur. The appearance of 
complications is difficult to predict. The aims of the present study were to evaluate the diagnostic 
findings, clinical course, and prognostic factors of essential thrombocythaemia in Finnish patients. 
 
The present retrospective study consists of 170 ET patients from five hospitals diagnosed and 
followed during the years 1980-1996. At the time of the diagnosis the median age of the patients 
was 52 years, one third of them being younger than 45 years. Two thirds of the patients were 
diagnosed by chance. About two thirds had a platelet count < 1000 x 109/l. The diagnosis of ET 
was supported by an increased number of megakaryocytes with an abnormal morphology in a 
bone marrow aspirate, aggregation defects in platelet function studies, and the presence of 
spontaneous erythroid and/or megakaryocytic colony formation in in vitro cultures of 
haematopoietic progenitors. About 70 % of the patients had spontaneous colony formation, while 
about 30 % had a normal growth pattern. 
 
At diagnosis or during the follow-up only a fifth of the patients remained asymptomatic. 
Approximately half had a major thrombohaemorrhagic complication. The proportion of the 
patients suffering from a thrombotic complication was as high as 45 %. About a fifth had major 
bleeding problems. Half of the patients had microvascular symptoms. Age over 60 years 
predicted a risk of major bleedings, but the occurrence of thrombotic complications was similar 
in all age groups. In multivariate analysis, male gender, smoking in female patients, the presence 
of any spontaneous colony formation, and the presence of spontaneous megakaryocytic colony 
formation in patients younger than 45 years were identified as risk factors for thrombotic 
complications.  
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Pregnant ET patients had an increased risk of complications. Forty-five per cent of the 
pregnancies were complicated and 38 % of them ended in stillbirth. A previous complicated 
pregnancy predicted problems in subsequent pregnancies. Treatment with acetylsalicylic acid 
alone or in combination with platelet lowering drugs improved the outcome of the pregnancy. 
 
The present findings about risk factors in ET as well as treatment outcome in the pregnancies of 
ET patients should be taken into account when planning treatment strategies for Finnish patients. 
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INTRODUCTION 
 
Essential thrombocythaemia (ET) is classified with polycythaemia vera (PV), chronic myeloid 
leukaemia (CML), and myelofibrosis (MF) as a chronic myeloproliferative disease 
(MPD).Thrombocytosis, i.e. an elevation of the platelet count, is a constant feature in ET. Clonal 
proliferation leading to enhanced platelet production may appear in all MPDs and, occasionally, 
also in myelodysplastic syndromes (MDS) (Kutti 1990, Schafer 2004). Reactive thrombocytosis 
(RT), on the other hand, includes thrombocytosis associated with acute or chronic infections or 
inflammations, malignancies, iron deficiency, bleedings, as well as thrombocytosis after 
splenectomy (Kutti 1990, Schafer 2004). 
 
As a result of the increased use of automated blood cell counters thrombocytosis has become a 
common chance finding. The differential diagnosis of thrombocytosis is crucial, since the clinical 
course, need of therapy, and prognosis are different in patients with RT and MPDs. The clinical 
course of ET is characterized by serious, even fatal, thrombotic and bleeding complications, 
whereas patients with RT do not suffer from thrombohaemorrhagic complications (Murphy 1983, 
Schafer 1984, Mitus and Schafer 1990b, Pearson 1991, Randi et al. 1991, Buss et al. 1994, 
Griesshammer et al. 1999a). Many patients with ET may remain asymptomatic for years, and the 
prediction of complications is difficult. 
 
The present thesis deals with the diagnosis and clinical course of ET and investigates predictive 
factors for thrombohaemorrhagic complications which may be of use in difficult treatment 
decisions.  
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REVIEW OF THE LITERATURE 
 
ET is a chronic myeloproliferative disease characterized by clonal proliferation of 
megakaryocytes and a constantly elevated platelet count (Dameshek 1951, Fialkow et al. 1981). It 
has been previously regarded as a disease of middle-aged or elderly patients (Tobelem 1989). 
However, with the frequent use of automated blood cell counters ET is increasingly diagnosed in 
young and asymptomatic patients (Mitus et al. 1990a, McIntyre et al. 1991, Randi et al. 1999a), 
and some authors consider it the most frequent of all MPDs (Tobelem 1989, Kutti 1990). 
According to population-based epidemiologic studies, the incidence rates of ET range from six to 
25 patients per one million inhabitans annually (Mesa et al 1999, Jensen et al. 2000b, Johansson 
et al. 2004). There is a slight female preponderance (Cortelazzo et al. 1990, Fenaux et al. 1990, 
Colombi et al. 1991, Randi et al. 1991, Lengfelder et al. 1998, Besses et al. 1999, Jensen et al. 
2000b). The morbidity of the patients with ET is due to thrombotic and bleeding complications 
(Schafer 1984). Earlier studies emphasized the importance of bleeding complications (Gunz 
1980, Murphy 1983, Bellucci et al. 1986), but more recent studies have revealed that the majority 
of the complications are thrombotic (Cortelazzo et al. 1990, Lengfelder et al. 1998, Besses et al. 
1999). The increased risk of bleeding has been associated with a high platelet count (Bellucci et 
al. 1986, Budde et al. 1993, Budde and van Genderen 1997), whereas factors contributing to the 
appearance of thrombotic events are not clearly established. The concept of risk-stratified 
management is generally accepted in ET (Harrison 2005a).  
 
Pathogenesis of ET 
 
Normal megakaryopoiesis 
 
Megakaryopoiesis is regulated by several cytokines. The most important regulator is 
thrombopoietin (TPO), a polypeptide of 353 amino acids (Bartley et al. 1994, Kato et al. 1995). 
TPO has several effects on normal megakaryopoiesis. It increases the size and number of 
megakaryocytes, stimulates the expression of platelet-specific markers, and stimulates 
endomitosis and polyploidy in megakaryocytes (Bartley et al. 1994, de Sauvage et al. 1994, 
Kaushansky et al. 1994). TPO is a megakaryocyte colony-stimulating factor acting in synergy 
with other molecules including interleukin-3 (IL-3), stem cell factor, and erythropoietin (EPO) to 
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stimulate megakaryocytic growth (Broudy et al. 1995). Together with EPO, TPO also promotes 
the growth of erytroid progenitor cells (Kaushansky et al. 1996, Broudy et al. 1997). 
Transforming growth factor β1 (TGF β1) is a potent enhancer of bone marrow stromal TPO 
expression which, in turn, stimulates the expression of TGF β receptors on megakaryocytes, thus 
increasing the sensitivity of megakaryocytes to suppression by TGF β itself (Sakamaki et al. 
1999). In vivo TPO increases the number of megakaryocytes and platelets in mice by a factor of 
up to ten (Bartley et al. 1994, de Sauvage et al. 1994, Lok et al. 1994) compared to the normal 
levels. In addition, TPO increases the numbers of all types of haematopoietic progenitors (Bartley 
et al. 1994, Lok et al. 1994). It has been reported that TPO sensitizes platelets to the aggregatory 
effects of well-known agonists, such as thrombin, collagen, and adenosine diphosphate (ADP), 
even though it does not cause platelet aggregation in the absence of these substances (Chen et al. 
1995, Usuki et al. 1997). Platelets regulate the concentration of TPO in plasma, and the 
megakaryocyte mass is inversely related to the levels of TPO (Kuter and Rosenberg 1995, 
Emmons et al. 1996). 
 
TPO is the ligand for the cytokine receptor c-Mpl which has been shown to be expressed on 
megakaryocytes, their precursors, and platelets (Vigon et al. 1992). In addition, the progeny of 
normal human burst forming units - erythroid (BFU-E) contains Mpl receptor ribonucleic acid 
(RNA) (Broudy et al. 1997). The Mpl receptors bind TPO with high affinity, internalize, and 
degrade it (Broudy et al. 1997, Fielder et al. 1997, Li et al. 1999).  
 
Megakaryopoiesis in thrombocytosis  
 
Despite an increased platelet and megakaryocytic mass in ET, TPO levels have in most studies 
been normal or even elevated (Tahara et al. 1996, Cerrutti et al. 1997, Horikawa et al. 1997, 
Pitcher et al. 1997, Hou et al. 1998, Wang et al. 1998, Harrison et al. 1999b, Li J et al. 2000). 
TPO levels do not differentiate between primary and reactive thrombocytosis (Cerrutti et al. 
1997, Harrison et al. 1997, Hou et al. 1998). It has been suggested that the interaction between 
TPO and TPO receptors play a crucial role in the pathogenesis of ET, and an alteration in the 
feedback interaction between the ligand and its receptor may result in thrombocytosis (Li J et al. 
2000). The number of platelet TPO receptors in ET is significantly decreased, TPO/receptor 
complex formation is reduced, and a tenfold reduction in platelet c-Mpl RNA has been reported 
(Horikawa et al. 1997, Harrison et al. 1999b, Li J et al. 2000). In immunohistochemical studies a 
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markedly decreased c-Mpl expression has been reported in up to 68 % of patients with ET (Mesa 
et al. 2002). Normal concentrations of c-Mpl mRNA of bone marrow cells have been detected 
only in a few ET patients (Moliterno et al. 1998, Yoshida et al. 1998). The platelet-dependent 
TPO clearance has been reported to be reduced, and may only be 25 % of the normal (Li J et al. 
2000). Therefore, a defect in down-regulation obviously contributes to the normal or elevated 
TPO levels in patients with ET. In one study there was some evidence of insufficient protein 
phosphorylation stimulated by TPO binding in ET platelets (Li J et al. 2000), but this has not 
been verified in other studies (Horikawa et al 1997). 
 
In familial thrombocythaemia, which is a rare chronic MPD with autosomal-dominant 
inheritance, activating splice mutations in intron 3 of the TPO gene leading to increased TPO 
synthesis as well as an activating mutation of the c-Mpl gene have been detected (Kondo et al. 
1998, Wiestner et al. 1998, Ghilardi et al. 1999, Ding et al. 2004). To date, no TPO or c-Mpl 
mutations have been reported in sporadic ET (Kiladjian et al. 1997, Harrison et al 1998b, Taksin 
et al. 1999, Allen et al. 2001). 
 
Clonality 
 
Traditionally ET has been considered to be a clonal disorder originating from a pluripotent 
haematopoietic stem cell. Female cells express randomly only one active X chromosome. 
Clonality assays utilize the polymorphism of the X chromosome by X-chromosome inactivation 
patterns (X-CIPs). Fialkow et al. (1981) reported that in ET, platelets, erythrocytes, and 
neutrophils express a single isoenzyme type of glucose-6-phosphate dehydrogenase (G6PD) in 
female patients heterozygous for G6PD isoenzymes. Later studies have used different 
deoxyribonucleic acid (DNA) methylation patterns of active and inactive X-chromosomal genes, 
such as phosphoglycerate kinase, hypoxanthine phosphoribosyl transferase, and the human 
androgen receptor genes (Anger 1990, Gale et al. 1996). The analysis of the RNA expression of 
iduronate-2-sulphatase, palmitoylated membrane protein p55, and G6PD, has allowed the 
evaluation of clonality of platelets and subpopulation of cells (Harrison et al. 1998a). The 
methods exploiting X-CIPs are limited, because a significant proportion (21-31 %) of healthy 
females have a skewed pattern of X-chromosome inactivation and skewed X-inactivation patterns 
occur associated with increasing age (Busque et al. 1996, Champion et al. 1997, Gale et al. 1997). 
Clonality assays are informative only in approximately a quarter of patients with ET (Harrison et 
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al. 1999a).  
 
In recent reports the proportion of ET patients with clonal haematopoiesis has varied from 42 to 
74 % (El-Kassar et al. 1997, Ferraris et al. 1999, Harrison et al. 1999a, Chiusolo et al. 2001, Shih 
et al. 2002). In the study of El-Kassar et al. (1997) the majority of ET patients had clonal 
haematopoiesis which, in some patients, was restricted only to platelets and the megakaryocytic 
lineage. In other studies no evidence of restrictions to the megakaryocytic lineage could be 
detected (Harrison et al. 1999a, Chiusolo et al. 2001). Clonal haematopoiesis has been regarded 
as a prognostic factor in ET (see later) (Harrison et al. 1999a, Chiusolo et al. 2001, Shih et al. 
2002), but this has not been found in all studies (El-Kassar et al. 1997). 
 
Haematopoietic progenitors in ET 
 
The in vitro cultures of haematopoietic progenitors have created new insight into the 
pathophysiology of ET. The first haematopoietic progenitor identified with in vitro cultures was 
termed CFU-C (colony forming unit in culture) and the colonies comprised mainly neutrophils 
and macrophages (Ichikawa et al. 1966, Pike and Robinson 1970). Later, Guilbert and Iscove 
(1976) induced an improved culture assay for granulocyte–macrophage colonies (CFU-GM) in 
methyl cellulose partially replacing serum by selenite, transferrin, albumin, and lecithin. This 
assay supports both granulocyte-macrophage and erythroid colony formation. Cultures for 
committed erythroid progenitors (CFU-E, colony forming unit - erythroid) (Stephenson et al. 
1971) and their antecedents, burst forming units - erythroid (BFU-E) (Axelrad et al. 1973), were 
established by supplementing culture media with EPO. The culture assay for megakaryocyte 
progenitors (CFU-Meg, colony forming unit - megakaryocyte) was described later (Metcalf et al. 
1975, Vainchenker et al. 1979). Different semisolid media (plasma clot, methyl cellulose), culture 
conditions (with either plasma or serum), and sources of progenitors (bone marrow, peripheral 
blood) have been used. The growth of megakaryocytic progenitors has been stimulated with 
phytohaemagglutinin-stimulated leukocyte conditioned medium (PHA-LCM) or with the plasma 
of patients with aplastic anaemia. In ET the number of CFU-Meg in bone marrow has been 
reported to be normal in most studies (Komatsu et al. 1986, Juvonen et al. 1987), even though 
increased numbers of progenitors have also been found (Kimura et al. 1987). With one exception 
(Croizat et al.1983) the number of circulating CFU-Meg has been reported to be increased 
(Hibbin et al. 1984, Grossi et al. 1987, Han et al 1987, Juvonen et al. 1987, Mazur et al. 1988, 
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Florenza et al. 1989, Han et al. 1989). The growth of erythroid or granulocyte-macrophage 
colonies has been either increased or within normal limits (Partanen et al. 1983, Eridani et al. 
1984, Eridani et al. 1987, Juvonen et al. 1987). 
 
The in vitro growth of erythroid or megakaryocytic colonies without the addition of EPO or 
megakaryocytic growth factors is called endogenous or spontaneous colony formation. This 
phenomenon is seen neither in normal persons nor in patients with RT but, in contrast, it has been 
shown to be present in a variable proportion of patients with ET and other MPDs (Partanen et al. 
1983, Eridani et al. 1984, Komatsu et al. 1986, Eridani et al. 1987, Grossi et al. 1987, Han et al. 
1987, Juvonen et al. 1987, Kimura et al. 1987, Hamagucchi et al. 1988, Battegay et al. 1989, 
Dudley et al. 1989, Florensa et al. 1989, Han et al. 1989, Abgrall et al. 1992, Turhan et al. 1992, 
Juvonen et al. 1993, Florensa et al. 1995, Rolovic et al. 1995). In the previous studies (as above) 
the proportion of ET patients with spontaneous megakaryocytic colony formation has ranged 
between 63 and 100 %. The percentage of ET patients with spontaneous erythroid colony 
formation varies widely, approximately from 30 to 100 %, with a median of 65 % (Croizant et al. 
1983, Partanen et al. 1983, Eridani et al. 1984, Eridani et al. 1987, Juvonen et al. 1987, Kimura et 
al. 1987, Dudley et al. 1989, Florensa et al. 1989, Turhan et al. 1992, Juvonen et al. 1993, 
Florensa et al. 1995, Rolovic et al 1995).  
 
The precise mechanism of spontaneous colony formation in MPD has remained obscure. Normal 
human megakaryocytes synthesize and secrete a number of cytokines including IL-1α, ΙL−1β, 
IL-3, IL-6, and granulocyte-macrophage colony stimulating factor (GM-CSF) (Jiang et al. 1994, 
Wickenhauser et al. 1995). Cytokines originating from the added plasma have been excluded as a 
reason for spontaneous colony growth (Kobayashi et al. 1993). The elimination of the role of 
accessory cells by CD34 positive cell selection leads to the disappearance of spontaneous 
megakaryocyte colony formation, suggesting that other cells contribute to one or more factors 
relevant for the proliferation of progenitors (Kobayashi et al. 1993). Several studies have shown 
that megakaryocyte progenitors are highly sensitive to low concentrations of various cytokines, 
such as TPO, IL-3, IL-6, and GM-CSF (Kobayashi et al. 1993, Zauli et al. 1994, Taksin et al. 
1999, Axelrad et al. 2000, Kawasaki et al. 2001, Mi et al. 2001), but their depletion in the culture 
medium is unable to inhibit spontaneous colony formation (Li Y et al. 1994). Decreased 
sensitivity of megakaryocyte progenitors to the inhibitory effect of negative regulators of 
thrombopoiesis, such as TGF β1, has also been proposed (Zauli et al. 1993). Human c-Mpl proto-
  15
oncogene is obviously important for the spontaneous megakaryocytic colony formation in ET, 
because soluble c-Mpl receptors and antisense oligonucleotides directed at c-mpl RNA have been 
reported to inhibit spontaneous colony formation (Li Y et al. 1996), but this effect could not be 
detected with antibodies to TPO (Taksin et al. 1999). Recently, the presence of Janus kinase 2 
(JAK2) mutation (see later) has been identified in endogeneous erythroid colonies (Baxter et al. 
2005), whereas a JAK2 inhibitor blocks endogenous erythroid colony growth (Ugo et al. 2004). 
 
Cytogenetics and molecular pathogenesis  
 
Cytogenetic abnormalities, which are non-specific, appear only in a minority of patients with ET 
(Sessarego et al. 1989, Bench et al. 2001, Swolin et al. 2001). In addition, cytogenetic 
abnormalities in general and especially abnormalities of chromosome 17p have not been linked to 
the natural history of the disease but rather to transformation to acute leukaemia caused by 
treatment with hydroxyurea (Sessarego et al. 1989, Sterkers et al. 1998, Merlat et al. 1999, 
Bernasconi et al. 2002). During recent years over-expression of polycythaemia rubra vera-1 gene 
(PRV-1) in neutrophils, described first in the patients with PV, has been found also in ET 
(Temerinac et al. 2000, Klippel et al. 2002, Teofili et al. 2002, Tefferi et al. 2003). The 
mechanism of this finding has been suggested to be a failure to downregulate PRV-1 in 
granulocytes emigrating from the bone marrow to blood rather than an upregulation of the PRV-1 
gene in clonal haematopoiesis (Bock et al. 2003).  
 
The recent finding of an association between an activating JAK2 mutation and bcr/abl negative 
MPDs has revealed new insight into the primary oncogenic event in these disorders. JAK2 is a 
cytoplasmic protein tyrosine kinase that mediates the signalling downstream of cytokine 
receptors (Yeh and Pellegrini 1999, Rane and Reddy 2002). The cytokine receptor/ligand 
complex results in autophosphorylation and transphosphorylation of both the receptor and 
receptor-associated JAK, which activates substrate molecules such as signal transducers and 
activators of transcription (STAT) proteins (Carter-Su and Smit 1998, Benekli et al. 2003). The 
JAK/STAT signal transduction is important in cellular proliferation and cell survival (Levy and 
Darnell 2002, Benekli et al. 2003). The activating mutation of JAK2 has been found in 23-57 % 
of the patients with ET, in 65-97 % of the patients with PV, and in 35-57 % of the patients with 
MF (Baxter et al. 2005, Jones et al. 2005, Kralovics et al. 2005, Levine et al. 2005). It has been 
suggested that the resulting kinase activity caused by JAK2 mutation is critical for the phenotype 
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of the MPD: low kinase activity would lead to ET, intermediate activity level to PV, and very 
high activity level to MF (Vainchenker and Constantinescu 2005). According to the presence of 
the JAK2 mutation, ET patients may be divided into two biologically distinct subgroups, JAK2-
positive and JAK2-negative patients (Campbell and Green 2005). The presence of JAK2 
mutation in ET has been suggested to promote the development of a PV phenotype (Wolanskyj et 
al. 2005). 
 
Abnormalities in platelets  
 
A great number of functional, structural, and metabolic platelet abnormalities have been reported 
in ET (Table 1). They present either with hypo- or hyperfunction of platelets (Schafer 1984). 
However, attempts to correlate these abnormalities to clinical events have resulted in 
controversies (Pareti et al. 1982, Barbui et al. 1983, Baker and Manoharan 1988, Sehayek et al. 
1988, Wehmeier et al. 1989, Wehmeier et al. 1990, Finazzi et al. 1996, Wehmeier et al. 1997, 
Raszeja-Specht et al. 2001). There are several explanations for the conflicting results. Some 
platelet abnormalities in ET may be secondary to platelet activation in vitro having thus no 
correlation to platelet function in vivo (Remaley et al. 1989). ET patients may have more than one 
platelet defect simultaneously (Schafer 1984). Abnormalities in platelet function studies may also 
vary due to methodological differences (Balduini et al. 1991), progression of the disease (Baker 
and Manoharan 1988, Wehmeier et al. 1989) or cytoreductive therapy (Catani et al. 1991).  
 
There are reports indicating that factors other than platelets alone also play a role in the 
haemostatic complications in ET. Several studies have revealed alterations of the fibrinolytic 
system in MPD. Elevated plasma levels of the plasminogen activator inhibitor (PAI-1) (Cancelas 
et al. 1994), dysbalance between elevated platelet PAI-1 activity and low platelet activity of the 
tissue-type plasminogen activator (Bazzan et al. 1993), and activation of fibrinolysis (Wieczorek 
et al. 1995) have been described. Other possible explanations include functional abnormalities of 
natural anticoagulants (Bucalossi et al. 1996, Harrison et al. 2002, Amitrano et al. 2003). 
Recently, endothelial damage and thrombin activation have been described in ET and PV. 
Activated neutrophils and monocytes promote coagulation by formation of platelet-leukocyte 
aggregates which, in turn, promote monocyte tissue factor expression and release of 
inflammatory cytokines, leading to endothelial activation and damage (Celi et al. 1994, Falanga 
et al. 2000, Jensen et al. 2001, Villmow et al. 2002, Falanga et al. 2005). 
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Table 1. Platelet abnormalities in essential thrombocythaemia (based on the thesis of Perry J.J. van Genderen, 1999a). 
1. Platelet function in vitro 
a. hypoaggregation with adrenaline, adenosine 5’-diphosphate (ADP), collagen, arachidonic acid, and prostaglandin 
peroxides (Fabris et al. 1981, Pareti et al. 1982, Schafer 1984, Sehayek et al. 1988, Wehmeier et al. 1989, Zahavi et 
al. 1991) 
b. spontaneous platelet aggregation (Wu 1978, Cortelazzo et al. 1980, Hehlman et al. 1988) 
c. circulating platelet aggregates (Wu 1978, Villmow et al. 2002) 
d. increased plasma levels of platelet-derived products (Ireland et al. 1982, Wehmeier et al. 1989) 
e. circulating activated platelets (Wehmeier et al. 1991b, Griesshammer et al. 1999, Bermejo et al. 2004) 
2. Platelet function in vivo 
a. prolonged bleeding time (Murphy et al. 1978, Pareti et al. 1982, Schafer 1984) 
b. reduced platelet life span (Brodsky et al. 1972, Berild et al. 1987) 
c. platelet activation in vivo (Rocca et al. 1995, Jensen et al. 2000a) 
3. Platelet morphology 
a. increased platelet distribution width at normal or elevated mean platelet volume (van der Lelie and von dem Borne 
1986, Sehayek et al. 1988, Majer et al. 1991, Osselaer et al. 1997) 
b. hypertrophy of dense tubular and open canalicular system (Zeigler et al. 1978) 
c. reduced number of dense bodies containing adenine nucleotides and serotonin (Spaet et al. 1969, Russell et al. 1981, 
Pareti et al. 1982) 
d. reduced α-granule stores of β-thromboglobulin, fibrinogen, platelet-derived growth factor, von Willebrand factor 
(Boughton et al. 1978, Ireland et al. 1982, Gersuk et al. 1989, Castaman et al. 1995) 
4. Platelet membrane receptors 
a. reduction of glycoprotein (GP) IIb/IIIa (Gugliotta et al. 1983, Mazzucatio et al. 1989, Jensen et al. 2000a) 
b. reduction of GP Ib (Mazzucato et al. 1989, Jensen et al. 2000a) 
c. increase of GP IV (thrombospondin) (Legrand et al. 1991, Thibert et al. 1995, Jensen et al. 2000) 
d. decreased sialylation of GP Ib and IIIa (Clezardin et al. 1985) 
e. lack of α-adrenergic receptors, leading to lack of aggregation with adrenaline (Kaywin et al. 1978) 
f. decreased number of prostaglandin D2 receptors, leading to increased resistance to inhibitory prostaglandins (Cooper 
and Ahern 1979, Cortelazzo et al. 1988) 
g. absence of GP Ia-IIa, leading to lack of aggregation with collagen (Handa et al. 1995) 
h. increased expression of Fc receptors (Moore et al. 1981) 
i. decrease in fibrinogen binding sites (Mazzucato et al. 1989, Mistry et al. 1991) 
5. Platelet metabolism 
a. abnormalities in uptake and storage of serotonin (Cortelazzo et al. 1985) 
b. abnormalities in arachidonate metabolism including lipoxygenase deficiency (Okuma and Uchino 1979, Russell et 
al. 1981, Smith and Martin 1982, Takayama et al. 1983, Zahavi et al. 1991, van Genderen et al. 1994b, Rocca et al. 
1995, Tomo et al. 1997) 
6. Platelet signal transduction 
a. impaired receptor-response coupling in adrenaline-insensitive platelets (Kaywin et al. 1978, Swart et al. 1985a, 
Swart et al. 1985b) 
b. defects in calcium mobilization and exchange across platelet membranes (Fujimoto et al. 1989, Ushikubi et al. 1990) 
 
 
Acquired von Willebrand syndrome 
 
A number of studies of MPD have shown a correlation between the platelet count and the loss of 
large von Willebrand factor (vWF) multimers in plasma (Budde et al. 1993, van Genderen et al. 
1994a, van Genderen et al. 1996, Budde et al. 1997, van Genderen et al. 1997b, Michiels et al. 
2001). This results in a functionally relevant defect leading to a bleeding tendency especially with 
high platelet counts. vWF is a key factor in haemostasis mediating the adhesion of platelets to 
vascular injury site and inducing platelet aggregation (Ruggeri 2001). Regulation of the size and 
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function of vWF is mediated by a specific vWF cleaving protease, ADAMTS13 (Furlan et al. 
1996, Levy et al. 2001). Normally the cleavage site for ADAMTS13 in the vWF subunit is 
protected. The function of vWF declines with increasing platelet counts in MPD and also in RT 
(van Genderen et al. 1996, Favoloro 2000). The disappearance of large multimers has been 
reported to be caused by decreased survival after secretion (van Genderen et al. 1997b) and this 
may be due to the increased proteolysis of vWF (Tsai 1996, Levy et al. 2001). It has been 
suggested that in thrombocytosis the increased platelet count facilitates the interaction between 
the platelet surface receptor GP Ib and vWF leading to conformational changes in vWF thus 
allowing ADAMTS13 to reach its cleavage site. 
 
Diagnosis of ET 
 
Thrombocytosis (platelet count > 400 x 109/l) can be found both in MPDs and in several 
disorders as a reactive phenomenon. RT may be present in chronic inflammation, iron deficiency, 
malignancy, and bleeding (Kutti 1990, Mitus and Schafer 1990b, Kutti and Wadenvik 1996). RT 
is far more common than myeloproliferative thrombocytosis (Griesshammer et al. 1999a). In a 
study of 280 patients with platelet counts at least once higher than 1000 x 109/l, 231 (82 %) had 
RT, 38 (14 %) an MPD, and 11 (4%) thrombocytosis of an unknown cause (Buss et al. 1994). 
The differentiation between reactive and myeloproliferative thrombocytosis is essential since RT 
does not predispose to thrombohaemorrhagic complications (Schafer 1984, Griesshammer et al. 
1999a). The diagnosis of ET requires the exclusion of RT as well as of the other MPDs, such as 
PV, CML, and MF (Murphy et al. 1986, Murphy et al. 1997).  
 
The diagnostic criteria for ET of the Polycythemia Vera Study Group (PVSG) are based on the 
exclusion of other causes of thrombocytosis (Table 2). In recent years there have been attempts to 
define positive criteria and to find appropriate tools for the diagnosis of ET (Kutti and Wadenvik 
1996, Michiels and Juvonen 1997).  
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Table 2. Diagnostic criteria for ET according to the Polycythemia Vera Study Group. All 
requirements should be fulfilled to establish the diagnosis. 
___________________________________________________________________________ 
 
1. Platelet count > 600 x 109/l 
2. Haemoglobin < 130 g/l or normal red cell mass (males <36 ml/kg, females < 32 
ml/kg) 
3. Stainable iron in bone marrow or failure of iron therapy  (< 10 g/l rise in haemoglobin 
after one month of iron therapy)  
4. No Philadelphia chromosome 
5. Collagen fibrosis of marrow 
a. absent or 
b. < 1/3 biopsy area without both splenomegaly and leukoerythroblastic reaction 
6.  No known cause for reactive thrombocytosis 
___________________________________________________________________________ 
 
Bone marrow biopsies of untreated ET patients reveal an increase in the number and clustering of 
giant megakaryocytes with multilobulated nuclei (Thiele et al. 1988, Thiele et al. 2000, Thiele et 
al. 2003, Michiels 2004a, Michiels 2004b, Thiele et al. 2005). In some studies the platelet 
distribution width (PDW) has turned out to be useful in the differential diagnosis of 
thrombocytosis (Dudley et al. 1989, Osselaer et al. 1997). The DNA content of megakaryocytes 
in ET patients has been reported to be higher than in patients with RT, and in two-colour flow 
cytometry thrombocythaemic patients show higher ploidy numbers than patients with RT (Ridell 
et al. 1990, Jacobsson et al. 1994). Serum TPO levels and platelet c-Mpl expression seem to be 
less useful due to considerable overlapping between myeloproliferative and reactive 
thrombocytosis (Cerrutti et al. 1997). There are several reports of the over-expression of PRV-1 
gene in ET (Teofili et al. 2002, Johansson et al. 2003a, Johansson et al. 2003b, Kralovics et al. 
2003, Griesshammer et al. 2004), but it has been demonstrated that PRV-1 is constitutively 
expressed in bone marrow cells (Bock et al. 2003), and quantitative neutrophil PRV-1 mRNA 
does not distinguish between myeloproliferative and reactive disorders (Tefferi et al. 2003). 
 
Due to age-related skewing, X-chromosomal clonality studies are informative only in female 
patients younger than 65 years thus limiting the use of these assays only to a quarter of the 
patients (Harrison et al. 1999a). In some studies merely 60-70 % of assessable ET patients have 
shown clonal haematopoiesis, while in the rest of the patients haematopoiesis has turned out to be 
polyclonal (El-Kassar et al. 1997, Harrison et al. 1999a, Chiusolo et al. 2001). In a recent study 
using novel clonality assays with five X-chromosomal genes the presence or absence of clonal 
haematopoiesis could be detected in 90 % of the female patients, 85 % of whom showed clonal 
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haematopoiesis (Liu et al. 2003). The recently found acquired mutation of JAK2 can be detected 
in approximately half of the ET patients (Baxter et al. 2005, Jones et al. 2005, Kralovics et al. 
2005, Levine et al. 2005). Thus, in the future it may provide a significant tool in the differential 
diagnosis of thrombocytosis. 
 
There are several reports of spontaneous colony formation of haematopoietic progenitors in ET. 
In different studies the proportions of the patients with spontaneous erythroid or megakaryocytic 
colony formation have ranged from 29 to 100 % and from 63 to 100 %, respectively (Partanen et 
al. 1983, Eridani et al. 1984, Komatsu et al. 1986, Eridani et al. 1987, Grossi et al. 1987, Han et 
al. 1987, Juvonen et al. 1987, Kimura et al. 1987, Hamaguchi et al. 1988, Mazur et al. 1988, 
Battegay et al. 1989, Dudley et al. 1989, Florensa et al. 1989, Han et al. 1989, Abgrall et al. 1992, 
Turhan et al. 1992, Juvonen et al. 1993, Florensa et al. 1995, Rolovic et al. 1995, Mi et al. 2001). 
In the largest study thus far, 77 % of the patients with ET showed spontaneous megakaryocytic 
and/or erythroid colony formation, whereas 23 % of the patients did not have any kind of 
spontaneous colony growth (Juvonen et al. 1993). Most studies suggest that spontaneous colony 
formation of BFU-E or CFU-Meg is not found in RT. However, in one study using a serum-free 
culture technique spontaneous colony formation was detected also in RT (Sawyer et al. 1994).  
 
Several reports have shown that the majority of patients with ET have insufficient aggregation 
responses in platelet aggregation studies (Yamamoto et al. 1984, Tobelem et al. 1989, Wehmeier 
et al. 1990, Zahavi et al. 1991). Most frequently aggregation abnormalities are detected, not only 
in response to adrenaline, but also in response to collagen and ADP. There is, however, 
considerable overlapping between myeloproliferative and reactive thrombocytosis, and there is 
no clear evidence of a clinical relevance of platelet aggregation studies in the diagnostic 
evaluation of thrombocytosis (Sehayek et al. 1988, Majer et al. 1991). 
 
The spleen volume studied by ultrasound or scintigraphy has been shown to differentiate between 
myeloproliferative and reactive disorders (Messinezy et al. 1988, Revesz et al. 1993, Picardi et al. 
2002).  
 
Dudley et al. (1989) have proposed a simple scoring system for the positive diagnosis of ET 
consisting of splenic enlargement on scan, presence of spontaneous colony formation of BFU-E, 
elevated PDW, elevated ATP/ADP ratio or the presence of clinical ischaemia. A proposal for new 
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diagnostic criteria for ET, which also considers the bone marrow findings and the presence of 
spontaneous colony formation, is shown in Table 3. The WHO classification of tumours 
published in 2001 emphasizes the histopathology of the bone marrow (Table 4). According to the 
WHO classification, the positive diagnostic criteria for ET are a sustained platelet count > 600 x 
109/l and a bone marrow biopsy showing proliferation of the megakaryocytic lineage. Other 
MPDs, MDS, and RT should be excluded.  
 
A proposed updated version of the PVSG criteria for ET includes the JAK2 mutation as a main 
diagnostic hallmark (Table 5) (Campbell and Green 2005). 
 
Table 3. Proposal for revised diagnostic criteria for ET (Michiels and Juvonen 1997). 
 
Diagnostic 
A1. Platelet count in excess of 400 x 109/l and no known cause for RT. 
A2. Increase in the number and clustering of enlarged and mature megakaryocytes with  
       hyperploid nuclei in bone marrow specimens. 
A3. No preceding or other allied subtype of myeloproliferative disorder or myelodysplastic  
       syndrome. 
Confirmative 
B1. Normal or elevated leukocyte alkaline phosphatase score, normal erythrocyte  
       sedimentation rate, and no fever or infection. 
B2. Normal or increased cellularity of bone marrow with or without the presence of 
       reticulin fibers in biopsy material. 
B3. Splenomegaly on palpation or diagnostic imaging. 
B4. Spontaneous erythroid colony formation and/or spontaneous megakaryocyte colony 
       formation in in vitro culture. 
 
 
 
  22
Table 4. WHO diagnostic criteria for ET (Imbert et al. 2001). All positive and negative 
criteria should be fulfilled to establish the diagnosis. 
 
Positive criteria 
1. Sustained platelet count > 600 x 109/l 
2. Bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic 
lineage with increased numbers of enlarged, mature megakaryocytes 
Negative criteria 
1. No evidence of PV 
Normal red cell mass or Hb < 18.5 g/dl in males, 16.5 g/dl in females 
Stainable iron in marrow, normal serum ferritin or normal MCV 
If the former condition is not met, failure of iron trial to increase red cell mass or Hb levels 
to the PV range 
2. No evidence of CML 
No Philadelphia chromosome and no bcr-abl fusion gene 
3. No evidence of chronic idiopathic myelofibrosis 
Collagen fibrosis absent and reticulin fibrosis minimal or absent 
4. No evidence of MDS 
No del(5q), t(3;3)(q21;q26), inv(3)(q21;q26) 
No significant granulocytic dysplasia, few if any micromegakaryocytes 
5. No evidence that thrombocytosis is reactive due to: 
Underlying inflammation, infection, neoplasm or prior splenectomy 
 
 
Table 5. A proposed updated version of the PVSG criteria for ET (Campbell and Green 
2005). Diagnosis of ET requires A1 + A2 + B3-6 (JAK2 mutation-positive ET) or A1 + B1-6 
(JAK2 mutation-negative ET). 
 
A1. Platelet count > 600 x 109/l 
A2. Acquired JAK2 mutation 
B1. No cause for a reactive thrombocytosis 
- e.g., normal inflammatory indices 
B2. No evidence of iron deficiency 
- stainable iron in the marrow or normal red cell mean corpuscular volume 
B3. No evidence of PV 
- haematocrit < midpoint of normal range or normal red cell mass in presence of 
normal iron stores 
B4. No evidence of chronic myeloid leukaemia 
- no Philadelphia chromosome or bcr-abl gene rearrangement 
B5. No evidence of myelofibrosis 
- no collagen fibrosis and < 2 reticulin fibrosis (using 0-4 scale) 
B6. No evidence of a myelodysplastic syndrome 
- no significant dysplasia 
- no cytogenetic abnormalities suggestive of myelodysplasia  
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Clinical manifestations 
 
At diagnosis the mean age of ET patients has been shown to be 50 - 60 years, and about a quarter 
of the patients are younger than 40 years (Michiels 2004b). There is a slight female 
preponderance (Table 6). Morbidity in ET is due to thrombotic and haemorrhagic events. The 
patients may remain asymptomatic for long periods, but serious, even life-threatening vascular 
events may occur also in young patients (Millard et al. 1990, Mitus et al. 1990a). 
  
Thrombosis 
 
Thrombotic complications including both arterial and venous thrombosis are the main cause of 
morbidity in ET (Iland et al. 1983, Bellucci et al. 1986, Grossi et al. 1988, Hehlmann et al. 1988, 
Lahuerta-Palacios et al. 1988, Chistolini et al. 1990, Cortelazzo et al. 1990, Fenaux et al. 1990, 
Colombi et al. 1991, Randi et al. 1991, Wehmeier et al. 1991a, Regev et al. 1997). Disturbances 
in cerebral or coronary circulation may lead to ischaemia and infarction even in young patients 
without any cardiovascular risk factors (Lahuerta-Palacios et al. 1988, Millard et al. 1990, 
McIntyre et al. 1991, Scheffer et al. 1991, Host and Saunamäki 1992, Koudstaal and Koudstaal 
1997, Ravandi-Kashani and Schafer 1997, Daya et al. 2004). Thrombosis may also be located in 
peripheral, skin, and abdominal arterial circulation (Chistolini et al. 1990, Cortelazzo et al. 1990, 
Colombi et al. 1991, Griesshammer et al. 1997, Ravandi-Kashani and Schafer 1997). ET-related 
disturbances of the cerebral circulation include transient ischaemia attacks (TIAs), cerebral 
infarction, migraine, and non-focal neurological symptoms such as dysarthria, visual 
disturbances, and postural instability (Preston et al. 1979, Jabaily et al. 1983, Colombi et al. 1991, 
Michiels et al. 1993, Arboix et al. 1995, Koudstaal and Koudstaal 1997, Michiels et al. 1997, 
Randi et al. 1998). A characteristic feature of the peripheral circulation is erythromelalgia, 
manifested in painful burning sensations in warm and red extremities. This platelet-mediated 
arteriolar inflammation and thrombosis may lead to acrocyanosis and peripheral gangrene 
(Preston et al. 1974, Salem et al. 1980, Michiels et al. 1985, Michiels and ten Kate 1992, 
Michiels et al. 2004c). In recent studies the incidence of venous thrombotic events has been less 
frequent than that of arterial events (Hehlmann et al. 1988, Cortelazzo et al. 1990, Fenaux et al. 
1990, Colombi et al. 1991). Deep vein thrombosis and pulmonary embolism are the most 
common venous complications, whereas thrombosis of portal, hepatic, splenic, sagittal, and 
retinal veins occurs with a lower frequency (Hehlmann et al. 1988, Cortelazzo et al. 1990, Fenaux 
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et al. 1990, Colombi et al. 1991, Imasawa and Iijima 2002, Randi et al. 2002).  
 
Bleeding 
 
ET is characterized by a tendency for recurrent bleedings from mucous membranes and easy 
bruising. Serious bleedings including gastrointestinal or intracranial haemorrhage are relatively 
infrequent and mostly associated with antiaggregation therapy (Hehlmann et al. 1988, Fenaux et 
al. 1990, Colombi et al. 1991). ET patients are also prone to postoperative bleedings after surgical 
procedures or after dental extraction (Schafer 1984, Mitus et al. 1990b).  
 
Incidence of thrombohaemorrhagic complications 
 
ET may be diagnosed as an incidental finding by routine blood testing. In different studies, some 
of which include also children, the proportion of asymptomatic patients at diagnosis varies from 
11 to 73 % (Table 6). Of the symptomatic patients the majority presents with microvascular 
disturbances (Bellucci et al. 1986, Chistolini et al. 1990, Cortelazzo et al. 1990, Fenaux et al. 
1990, Colombi et al. 1991). The incidence of thrombosis varies widely, largely depending on 
whether microvascular symptoms are included in the thrombotic events or not. Major thrombotic 
complications (excluding microvascular symptoms) at diagnosis have been reported in 9-43 % of 
the ET patients (Table 6), but Hehlmann et al. (1988) found an incidence as high as 80 %. After 
the diagnosis the reported rate of thrombosis varies from 7 to 17 % (Barbui et al. 2004b). 
 
Bleeding complications are less frequent than thrombotic events (4-38 %) and only a minority of 
the bleedings are serious (Table 6). In a review of 809 ET patients from 11 retrospective studies, 
36 % of the patients were asymptomatic at diagnosis, 41 % experienced microvascular symptoms, 
and 20 % had major arterial thrombosis, 17 % bleeding and 4 % venous thrombosis 
(Griesshammer et al. 1997).  
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Risk factors for thrombotic and bleeding complications 
 
Several studies have shown that a previous thrombotic event indicates an increased risk of 
thrombosis (Chistolini et al. 1990, Cortelazzo et al. 1990, Colombi et al 1991, Besses et al. 1999). 
The predictive value of other risk factors for thrombosis has varied in different studies. Age and 
sex have been found to correlate with the risk of thrombosis in some studies (Cortelazzo et al. 
1990, Randi et al. 1991, Randi et al. 1992, Besses et al. 1999, Shih et al. 2002), whereas in other 
studies no such correlation has been found (Chistoloni et al. 1990, Fenaux et al. 1990, Colombi et 
al. 1991, Watson and Key 1993, Bazzan et al. 1999). The platelet count does not predict 
thrombotic complications (Bellucci et al. 1986, Hehlmann et al. 1988, Chistolini et al. 1990, 
Cortelazzo et al. 1990, Fenaux et al. 1990, Colombi et al. 1991, Randi et al. 1991, Watson and 
Key 1993, Bazzan et al. 1999, Besses et al. 1999). The association of conventional cardiovascular 
risk factors with thrombotic complications in ET has been unclear. Two retrospective studies 
have assessed the predictive value of these factors as the primary goal. One study revealed 
smoking (Watson and Key 1993) and another hypercholesterolaemia (Besses et al. 1999) as a risk 
factor in ET. In addition, in the prospective study of Cortelazzo et al. (1995) which was not 
primarily aimed at studying risk factors, smoking correlated with an increased risk of thrombosis. 
However, in most studies conventional cardiovascular risk factors have not had any prognostic 
significance (Hehlmann et al. 1988, Cortelazzo et al. 1990, Fenaux et al. 1990, Bazzan et al. 
1999). Spontaneous megakaryocytic colony formation has in one previous study been associated 
with an increased risk for complications (Juvonen et al. 1993), whereas spontaneous erythroid 
colony formation showed no predictive value in three other studies (Ciaudo et al. 1998, Chiusolo 
et al. 2001, Vannucchi et al. 2004). Clonal haematopoiesis (Harrison et al. 1999a, Chiusolo et al. 
2001, Shih et al. 2002, Vannucchi et al. 2004) and PRV-1 mRNA expression (Johansson et al. 
2003b, Griesshammer et al. 2004) have been associated with an increased risk for 
thromboembolic events. 
 
The frequency of bleeding complications increases with the acquired von Willebrand syndrome, 
when the platelet count rises above 1000 x 109/l (Bellucci et al. 1986, Fenaux et al. 1990, van 
Genderen et al. 1994a, Tefferi et al. 2001b). Bleeding complications are also associated with anti-
aggregation therapy (van Genderen et al. 1997a, Schafer 2004). 
 
  26
Table 6. Characteristics and incidence of thrombotic and bleeding complications of patients with 
ET at diagnosis. Age and platelet counts are expressed as means (range). 
 
 
Author No. of 
patients 
Age Sex ratio
(F:M) 
Platelet count 
(x 109/l) 
Thrombosis 
(%) 
Bleeding 
(%) 
Microvascular 
symptoms (%) 
Asymptomatic
(%) 
Bellucci et al.  
(1986) 
Hehlmann et al.  
(1988) 
Chistolini et al. 
(1990) 
Cortelazzo et al.  
(1990) 
Fenaux et al.  
(1990) 
Colombi et al.  
(1991) 
McIntyre et al.  
(1991) 
Randi et al.  
(1991) 
Lengfelder et al.  
(1996) 
van Genderen et 
al. (1997a)   
Besses et al.  
(1999)  
Jensen et al.  
(2000a) 
94 
61 
100 
100 
147 
103 
56 
97 
101 
68 
148 
 
96 
50 
(6-90) 
58 
(10-82) 
49 
(2-80) 
50 
(17-82) 
60 
(18-83) 
59 
(9-88) 
29 
(12-40) 
54 
(40-73) 
58 
(10-83) 
57 
 
61 
(11-85) 
67 
(18-87) 
1.76 
1.10 
1.27 
1.56 
1.45 
1.34 
1.40 
1.43 
1.19 
0.70 
1.79 
2.60 
1200 
 
897 
(300-4000) 
1140 
(1000-3750) 
1135 
(600-3000) 
NA 
(700-2900) 
NA 
 
NA 
 
1090 
 
844 
(609-4000) 
922 
 
898 
(600-4006) 
1102 
22 
841 
9 
20 
18 
24 
21 
451 
43 
601 
25 
14 
38 
13 
10 
10 
18 
4 
7 
38 
13 
7 
9 
9 
42 
NA 
29 
36 
34 
33 
NA 
NA 
43 
9 
29 
23 
67 
11 
52 
34 
36 
73 
70 
28 
37 
21 
57 
52 
 
NA = not available 
1 Includes also microvascular symptoms 
 
Treatment 
 
The need for therapy and the optimal treatment of ET has been an area of debate. The platelet 
count does not predict the risk of complications. Many patients are asymptomatic at diagnosis 
and may remain asymptomatic for long periods. However, serious, even life-threatening 
complications may occur also in young patients, and an individual patient may suffer from both 
thrombotic and bleeding events at the same time. On the other hand, the potential risk of inducing 
secondary leukaemia with platelet lowering drugs is a matter of concern. 
 
There is a general consensus that treatment in ET has to be risk-adapted. It is evident that 
treatment is indicated in symptomatic patients and in asymptomatic patients with a history of a 
major thrombotic or bleeding episode (Cortelazzo et al. 1995, Tefferi et al. 2000, Tefferi 2001a, 
Schafer 2004). Platelet lowering treatment decreases the incidence of thrombohaemorrhagic 
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complications, even though it does not abolish them totally, and the patients may experience 
thrombotic complications with only slightly elevated platelet counts (Hehlmann et al. 1988, 
Fenaux et al. 1990, Pearson 1991, Cortelazzo et al. 1995, Regev et al. 1997, Lengfelder et al. 
1998). There are several risk-adjusted treatment strategies dividing the patients into low-, 
intermediate- or high-risk patients based on their age, history of bleeding or thrombosis, and 
platelet count (Barbui and Finazzi 1999, Michiels 1999, Tefferi 1999, Tefferi 2001a, Harrison et 
al. 2003, Barbui et al. 2004b, Schafer 2004, Harrison et al. 2005b).The efficacy of platelet 
lowering treatment in high-risk patients, i.e. patients aged more than 60 years or with a history of 
previous thrombosis, has been prospectively demonstrated by Cortelazzo et al. (1995). Limited 
data is available on the thrombohaemorrhagic risk in younger asymptomatic patients, and the 
optimal approach is unknown. Until now, the only prospective, controlled study in low-risk ET 
patients showed similar incidences of thrombohaemorrhagic complications in the ET patients and 
the controls, and a conservative approach was suggested for these patients (Ruggeri et al. 2003). 
Also in some other studies a low incidence of thrombohaemorrhagic complications in low-risk 
patients has been reported (Randi et al. 1999a, Tefferi et al. 2001b). The role of cardiovascular 
risk factors in treatment decisions is controversial (Cortelazzo et al. 1990, Watson and Key 1993, 
Bazzan et al. 1999, Tefferi 2001a).  
 
ET patients have been treated with a variety of cytotoxic drugs including melphalan, busulphan, 
chlorambucil, and radioactive phosphorus (32P), but the leukaemogenic potential of these drugs is 
well documented (Berk et al. 1986, van de Pette et al. 1986, Brandt and Anderson 1995, Balan 
and Critchley 1997). Hydroxyurea is the only platelet lowering drug, the efficacy of which in the 
prevention of thrombohaemorrhagic complications has been prospectively shown in a 
randomized study (Cortelazzo et al. 1995). However, the leukaemogenic potential of hydroxyurea 
is a matter of debate. Some non-randomized studies have indicated an increased risk of secondary 
leukaemia associated with the long-term use of hydroxyurea in ET (Weinfeld et al. 1994, 
Furgerson et al. 1996, Liozon et al. 1997). In larger studies the incidence of leukaemic 
transformation in ET patients treated with hydroxyurea as the only treatment has ranged from 0 to 
5 % (Nand et al. 1996, Murphy et al. 1997, Sterkers et al. 1998, Finazzi et al. 2000). Mutagenic 
studies have not supported the leukaemogenity of hydroxyurea (Hanft et al. 2000). Many authors 
agree that hydroxyurea as a single agent carries only a slightly elevated, if any, risk of leukaemic 
transformation (Tefferi 2001a, Barbui 2004a, Harrison 2005b). However, the sequential use of 
hydroxyurea with other cytotoxic drugs increases markedly the risk of leukaemic transformation 
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(14-33 % of the patients) (Murphy et al. 1997, Sterkers et al. 1998, Finazzi et al. 2000). The need 
for multiple treatments may, on the other hand, reflect an aggressive form of ET and a tendency 
more likely to transform.  
 
During recent years the concern of leukaemogenesis has encouraged the use of non-
leukaemogenic platelet lowering drugs including interferon alfa (IFN) and anagrelide, especially 
in younger patients. IFN is a biological response modifier which has myelosuppressive activity 
and an ability to antagonize the action of the platelet-derived growth factor without any 
mutagenic risk (Lengfelder et al. 1996, Elliot and Tefferi 1997, Barbui et al. 2004a). It normalizes 
the platelet count in approximately 80-90 % of the patients, but side effects impairing the quality 
of life necessitate drug cessation in a quarter of ET patients (Lengfelder et al. 1996). Anagrelide 
acts by inhibiting megakaryocyte maturation and platelet aggregation (Mazur et al. 1992, Petit et 
al. 1997, Tomer 2002). It reduces effectively the platelet count in 70-90 % of the patients 
(Silverstein et al. 1992, Petrides et al. 1998, Birgegård et al. 2004, Fruchtman et al. 2005). In 
some reports anagrelide has turned out to be relatively well tolerated (Silverstein et al. 1992), but 
in two prospective studies even 37-50 % of the patients discontinued the treatment because of 
neurological, gastrointestinal or cardiac side-effects (Mills et al. 1999, Birgegård et al. 2004). 
Leukaemic transformation has not been observed in long-term use (Storen and Tefferi 2001, 
Fruchtman et al. 2005). Recently, however, accelerated fibrotic transformation in ET patients 
using anagrelide has been reported (Harrison et al. 2005c). Up till now there is no controlled 
evidence of the efficacy of anagrelide or IFN to prevent thrombohaemorrhagic complications, 
though it is presumable that adequate lowering of the platelet count also prevents complications. 
However, a recent randomized study (PT1-trial) showed that the combination of anagrelide and 
low-dose acetylsalicylic acid (ASA) was not as effective as that of hydroxyurea and ASA in 
preventing arterial thrombotic complications and it also increased the risk of major bleedings 
(Harrison et al. 2005c). 
 
Due to the risk of aggravating the bleeding tendency, the use of ASA in MPDs was long 
controversial (Schafer 1984). However, thromboxane A2 (TXA2) biosynthesis is increased in ET 
and it can be suppressed with low-dose ASA (50-100 mg per day) (Rocca et al. 1995). There is 
evidence that enhanced formation of TXA2 by platelets reflects platelet activation in vivo, which 
precedes the development arterial thrombosis in ET (van Genderen et al. 1999b). ASA relieves 
effectively microvascular disturbances of the peripheral and cerebral circulation and reduces 
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recurrences of thrombotic events in symptomatic patients (van Genderen et al. 1995, 
Griesshammer et al. 1997, van Genderen et al. 1997a, Michiels 1999, Randi et al. 1999b). The 
role of low-dose ASA in the primary prevention of thrombosis in ET is a matter of debate. 
Recently the efficacy and safety of low-dose ASA to prevent thrombotic complications was 
shown in PV (Landolfi et al. 2004). The use of low-dose ASA in ET has been recommended in 
high-risk patients together with the use of platelet lowering drugs, but the benefit of the ASA 
treatment in low- and intermediate-risk patients is unclear (Tefferi 2001a, Barbui et al. 2004b, 
Elliott and Tefferi 2005). However, according to some management guidelines, ASA is 
recommended to all patients with ET (Campbell and Green 2005). There are only case-reports 
concerning the use of newer antiplatelet agents, such as clopidogrel, in patients with ET 
(Klinzing et al. 2001, Mosso et al. 2004). 
 
Prognosis 
 
ET may transform to myelofibrosis or acute leukaemia as part of the natural course of the disease. 
Knowledge of myelofibrotic transformation is scarce, but in the study of Cervantes et al. (2002) 
myelofibrosis was observed in 8 % at ten years and in 15 % at 15 years. In untreated patients the 
incidence of progression to acute leukaemia has been reported to be a sporadic phenomenon (<5 
%) (Fenaux et al. 1990, Sterkers et al. 1998, Cervantes et al. 2002, Barbui 2004a, Fruchtman 
2004). Leukaemic transformation is, however, significantly associated with cytotoxic treatment 
(see above) and cytogenetic abnormalities (Löfvenberg et al. 1990). 
 
Studies of the prognosis of ET are relatively few and controversial. Rozman et al. (1991) and 
Passamonti et al. (2005b) reported that the actuarial survival probability of ET patients was 
similar to that of the control population, whereas the Olmsted County and the Copenhagen 
County studies showed significantly lower survival for ET patients (Mesa et al. 1999, Jensen et 
al. 2000a). In younger patients a fourfold relative risk of mortality was found by Bazzan et al. 
(1999), whereas Tefferi et al. (2001b) reported that young females with ET show a similar 
survival compared to control population.  
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Pregnancy in ET 
 
Knowledge of pregnancies in ET patients is limited, and many reports contain small numbers of 
pregnant patients. Only a few reports with a relatively large patient number are available (Beressi 
et al. 1995, Cincotta et al. 2000, Wright and Tefferi 2001). In some previous studies the outcome 
of pregnancy has mostly been successful (Jones et al. 1988, Linares et al. 1988, Beard et al. 1991, 
Randi et al. 1994, Randi et al. 2000, Chow et al. 2002), but high rates of miscarriages have also 
been reported (Falconer et al. 1987, Radaelli et al. 1994, Beressi et al. 1995, Pagliaro et al. 1996, 
Bangerter et al. 2000, Cincotta et al. 2000). The risk of first-trimester abortion is increased, and 
placental insufficiency may lead to foetal growth retardation and intrauterine foetal death. 
According to two recent reviews, live birth can be expected in 50-59 % of the pregnancies 
(Vantroyen and Vanstraelen 2002, Griesshammer et al. 2003). Pregnancies may also be 
complicated by pre-eclampsia and preterm delivery. No prognostic factors for pregnancy 
complications have been found (Beressi et al. 1995, Cincotta et al. 2000, Wright and Tefferi 
2001). 
 
The reports of the results of treatment before or during the pregnancy have been conflicting 
(Falconer et al. 1987, Chow et al. 1992, Randi et al. 1994, Beressi et al. 1995, Pagliaro et al. 
1996, Bangerter et al. 2000, Cincotta et al. 2000, Randi et al. 2000, Wright and Tefferi 2001, 
Ruggeri et al. 2003). The use of low-dose ASA for the prevention of pregnancy complications 
was advantageous in the studies of Cincotta et al. (2000), Randi et al. (2000), and Bangerter et al. 
(2001). In the literature review of Griesshammer et al. (2003) the live-birth ratio among the 
patients treated with ASA alone or in combination was 68 % but in the untreated patients only 48 
%. Pagliaro et al. (1996) combined ASA successfully with low-molecular-weight heparin in a 
study of seven patients. However, no benefits of the ASA therapy in the prevention of 
miscarriages were observed in the largest published reports with 34 and 43 pregnancies from the 
Mayo Clinic (Beressi et al. 1995, Wright and Tefferi 2001). In most studies the number of ET 
patients treated with IFN during pregnancy has been too small for any definite conclusions 
(Feelders et al. 1994, Perez-Encinas et al. 1994, Thornley and Manorahan 1994, Vianelli et al. 
1994, Williams et al. 1994, Delage et al. 1996, Diez-Martin et al. 1996, Frezzato et al. 1996, 
Milano et al. 1996, Pulik et al. 1996, Shpilberg et al. 1996, Schmidt et al. 1998, Cincotta et al. 
2000, Vantroyen and Vanstraelen 2002). Hydroxyurea should be avoided during pregnancy due 
to the risk of teratogenic effects, though there have been reports of successful pregnancies after 
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exposure to hydroxyurea (Thauvin-Robinet et al. 2001). Anagrelide crosses the placental barrier 
and may lead to foetal thrombocytopenia. There are no adequate studies of the use of anagrelide 
during pregnancy, but, according to general view, the use of anagrelide in pregnant women 
should be avoided. 
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THE AIMS OF THE PRESENT STUDY 
 
The purpose of the present thesis was to study the findings at diagnosis and the diagnostic 
procedures in ET, to evaluate the clinical course of ET in Finnish patients, and to identify 
predictive risk factors which could be used in treatment decisions. 
 
The specific aims were as follows: 
- to assess the causes leading to diagnostic evaluation for ET and the presence of positive 
diagnostic findings (I). 
- to study the occurrence of thrombotic and bleeding complications during the course of the 
disease and their association with age, sex, platelet count and cardiovascular risk factors (III). 
- to analyse the diagnostic and predictive value of the in vitro colony formation of 
haematopoietic progenitors and platelet function tests (I and IV). 
- to clarify the transformation of ET to other myeloproliferative disorders (II). 
- to analyse the clinical course and outcome of pregnancies in ET as well as the effect of 
treatment on the outcome of pregnancy (V).  
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PATIENTS AND METHODS 
 
Patients 
 
The consecutive patients diagnosed as having ET during the years 1980-1995 were identified 
from the databases of the Helsinki University Central Hospital, Helsinki Municipal Hospitals, 
Jorvi Hospital, Peijas Hospital, and Central Hospital of Kanta-Häme. In addition, data of ET 
patients with pregnancies was asked from all Finnish university and central hospitals where 
patients with haematological diseases were treated (V). All hospital records of the patients were 
reviewed. Only the patients fulfilling the modified diagnostic criteria (below) of the PVSG 
(Murphy et al. 1997) on re-evaluation were included in the study. The bone marrow aspirates of 
128 patients were re-examined (E.J / S-E.J). 
 
The diagnosis of ET was established if the following criteria were fulfilled: 
- platelet count over 600 x 109/l for at least six months 
- no erythrocytosis and exclusion of iron deficiency 
- no Philadelphia chromosome (the karyotype analysis was not available in many patients with no 
or minimal leukocytosis) 
- no leukoerythroblastic blood picture or morphological abnormalities of erythrocytes compatible 
with myelofibrosis 
- no known cause of reactive thrombocytosis 
 
For thrombocytosis a shorter follow-up than six months was accepted if cytoreductive therapy 
had been started due to symptoms considered to be related to thrombocythaemia. Adequate iron 
stores were verified by normal serum iron, transferrin, and ferritin concentrations or by the 
presence of adequate iron stores in bone marrow. In 15 patients iron deficiency was corrected 
with iron therapy. 
 
Study I. The diagnostic evaluation and the clinical and laboratory data at diagnosis were 
retrospectively analysed in all 170 patients with ET fulfilling the diagnostic criteria on re-evaluation. 
At the diagnosis of ET the median age was 52 years (range 19-88 years), 54 years (range 21-88 
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years) in males and 50 years (range 19-85 years) in females. At the time of the diagnosis of ET the 
median platelet count was 885 x 109/l (range 496-2175 x 109/l). 
 
Study II. With the median follow-up time of 63 months (range 11-313 months) the development 
of erythrocytosis was evaluated in the patient population described above. 
 
Study III. The occurrence of thrombotic and bleeding complications and the history of vascular risk 
factors including smoking, hypertension, diabetes mellitus, and hypercholesterolaemia, were 
registered from the patient data. The data of vascular risk factors was available of 132 patients (70 
females and 62 males). All these patients were interviewed with a questionnaire. At the diagnosis the 
median age was 51 years (range 19-88 years) and the median platelet count 866 x 109/l (range 496-
2175 x 109/l). During the follow-up the median peak platelet count was 1000 x 109/l (range 600-
2800 x 109/l). The median follow-up time of the patients with one or more vascular risk factors was 
65 months (range 12-291 months) and that of those without risk factors 74 months (range 11-313 
months).  
 
Study IV. In vitro cultures of erythroid and megakaryocytic progenitors were analysed in 154 
patients and platelet aggregation studies in 55 patients to assess the predictive value of 
spontaneous colony formation and platelet function on the occurrence of thrombotic and bleeding 
complications. The median follow-up of this patient cohort was 60 months (range 11-313 
months). At the time of the diagnosis the median age was 49 years (range 19-88 years), and 55 
patients were younger than 45 years of age. Progenitors from bone marrow only were cultured in 
106 patients, from peripheral blood only in 17 patients, and from both bone marrow and 
peripheral blood in 31 patients. 
 
The in vitro cultures of haematopoietic progenitors were performed as part of the diagnostic 
evaluation in 134 patients (87 %) and during the follow-up in 20 patients with the median of 53 
months (range 11-168 months) after the diagnosis. One hundred and forty-seven patients had not 
received any platelet lowering treatment before the in vitro cultures of haematopoietic progenitors. 
In two patients platelet lowering treatment had been discontinued shortly prior to the cultures and in 
the other five patients several years before that (range 2-13 years). The proportion of the patients 
treated with platelet lowering treatment or ASA before the appearance of the first major 
complication was similar in the patients with a normal haematopoietic progenitor growth pattern and 
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in those with spontaneous colony formation (8 % vs 10 % and 30 % vs 21 %, respectively). Platelet 
function studies were carried out in 55 patients, in 30 patients at the time of the diagnosis and in 25 
patients during the follow-up with the median of 59 months from the diagnosis (range 4-216 
months). None of the patients was on ASA therapy at the time of the platelet function studies or 
during the preceding ten days. 
 
Study V. The hospital records of 16 females with 40 pregnancies at five Finnish hospitals during 
the years 1980-1998 were reviewed. In six patients the diagnosis of ET was established before the 
first pregnancy (median of 69 months, range 3-120 months before the pregnancy). In ten patients 
thrombocytosis was detected for the first time during a pregnancy.  In two of these a pregnancy 
ending in miscarriage within the preceding six months was also included in the present analysis. 
The median age of the patients at the diagnosis of ET was 27 years (range 19-38 years). The 
median initial platelet count was 1082 x 109 /l (range 605-2498 x 109/l), and the median follow-
up from the diagnosis was 78 months (range 17-168 months).  
 
Methods 
 
Evaluation of the clinical features and risk factors (studies I - V) 
 
Thrombohaemorrhagic complications were classified as follows: Arterial complications included 
disturbances in the cerebral circulation (cerebral infarction, transient ischaemic attack), 
myocardial ischaemia (angina pectoris, myocardial infarction), claudication, peripheral gangrene, 
and arterial thromboembolism. Transient disturbances of the peripheral circulation 
(erythromelalgia, Raynaud’s phenomenon) and the cerebral circulation (visual disturbances, 
dizziness, migraine, epilepsy) were classified as microvascular symptoms. Venous thrombosis 
consisted of deep venous thrombosis of the extremities diagnosed by ultrasound or venography, 
pulmonary embolism, intra-abdominal venous thrombosis, and recurrent thrombophlebitis. Major 
bleeding complications included bleedings requiring transfusion, hospitalization or surgical 
treatment, and gastrointestinal, intracranial and excessive procedure-related bleedings. 
 
The vascular risk factors were defined as follows: The patients who smoked during the study or 
had smoked within one year preceding the study period were classified as smokers. The patients 
who had stopped smoking more than one year before the diagnosis of ET and those who had 
  36
never smoked were regarded as non-smokers. Hypertension was recorded as a risk factor in the 
patients on antihypertensive treatment and in those who had repeatedly systolic blood pressure 
higher than 160 mmHg or diastolic blood pressure higher than 95 mmHg. Hypercholesterolaemia 
was defined as serum total cholesterol higher than 6.5 mmol/l and low density lipoprotein 
cholesterol higher than 3.5 mmol/l. Diabetes mellitus was defined as fasting blood glucose higher 
than 6.7 mmol/l repeatedly. 
 
A questionnaire was sent to all patients in Study III. The questions concerned symptoms and 
complications of the disease, presence of cardiovascular risk factors, history of pregnancies and 
operations, and medication. 
 
Treatment 
 
The choice of therapy was based on the clinical judgement of the physician. Cytotoxic treatment 
was avoided at least in younger patients unless they had thrombohaemorrhagic complications 
before or at the diagnosis of ET. Due to the retrospective nature of the present study, the 
treatment varied during the study period depending on the therapy generally recommended at the 
time of diagnosis as well as on the local treatment practice. During the study period the treatment 
strategies changed, especially with the reduced use of busulphan and increased use of IFN in 
young patients. Overall, 99 patients received platelet lowering treatment which included 
busulphan (n = 49), hydroxyurea (n = 39), 32P (n = 13), and IFN (n = 25). The treatment was 
started in 85 % of the patients because of a thrombotic or bleeding complication and in 15 % 
because of a high platelet count or preoperatively. The patients younger than 60 years were 
treated as frequently as older patients (58 % vs. 61 %, respectively). ASA was given to 98 
patients.  
 
Cultures of haematopoietic progenitors 
 
Megakaryocyte progenitors were cultured according to the method of Messner et al. (1982). For 
the cultures of progenitors from the bone marrow 1-2 ml of marrow was aspirated and diluted in 
Iscove’s Modified Dulbecco’s Medium (IMDM). For the cultures of peripheral blood precursors 
10-20 ml heparinized venous blood was collected. Mononuclear cells were isolated by 
centrifugation, washed, and resuspended in IMDM. The culture medium consisted of 30 % 
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plasma from a patient with aplastic anaemia with 5 % phytohaemagglutinin-stimulated leukocyte 
conditioned medium (PHA-LCM) (stimulated colony formation) or 30 % normal human plasma 
without PHA-LCM (spontaneous colony formation), 5 x 10-5M 2-mercaptoethanol, and 0.9 % 
methyl cellulose in IMDM. The final mononuclear cell concentration was 2 x 105/ml. 
Megakaryocytic colonies containing at least five cells with a non-granular, translucent cytoplasm 
and a distinct cell border of high refractivity were scored on the 14th day of culture.  
 
Erythroid and granulocyte-macrophage progenitors were cultured as described by Iscove et al. 
(1974) with the modification of Guilbert and Iscove (1976). For the cultures of bone marrow 
progenitors 1-2 ml of marrow was aspirated and diluted in IMDM, red cells were removed by 
sedimentation with 10 % dextran, the leukocyte-rich supernatant was collected, and the cells were 
washed. For the cultures of peripheral progenitors 10-20 ml of peripheral blood was collected, 
mononuclear cells were isolated by Ficoll-Isopaque gradient, washed, and resuspended in IMDM. 
The culture medium consisted of 0.8 % methyl cellulose, 20 % foetal calf serum, 1 % delipidated 
and deionized bovine serum albumin, 10-4 mercaptoethanol, 310 ug/ml fully iron saturated human 
transferrin, 20 % human leukocyte conditioned medium prepared in IMDM, and IMDM. The 
number of mononuclear cells in the cultures was 2 x 105/ml. Colony formation of erythroid 
progenitors was stimulated with erythropoietin (2 U/ml) and colony formation of granulocyte-
macrophage progenitors with leukocyte feeder layers as described by Pike and Robinson (1970). 
Erythroid colonies of at least eight cells were scored on the seventh day of culture for CFU-E and 
colonies with at least three subclusters on the 14th day of culture for BFU-E. The cultures of 
granulocyte-macrophage progenitors (CFU-GM) were scored on the seventh and 14th day for 
colonies containing 40 or more cells. 
 
Platelet function studies 
 
Platelet aggregation tests were carried out with the method described by Ludlam (1994) at the 
laboratory of the Finnish Red Cross Blood Transfusion Service. Platelet-rich plasma was diluted 
with autologous platelet-poor plasma to the platelet concentration of 250 x 109/l. The following 
aggregation-inducing agents were used: ADP (1 μg/ml, 3 μg/ml, 6 μg/ml), adrenaline (0.9 μg/ml, 
9 μg/ml), arachidonic acid (0.6 mmol/l, 1.2 mmol/l), ristocetin (1.25 mg/ml, 1.5 mg/ml), and 
collagen (0.42 μg/ml, 0.84 μg/ml). 
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Cytogenetic studies   
 
Conventional cytogenetic studies with G-banding were performed in 76 patients at the time of the 
diagnosis. 
 
Statistical analysis 
 
The statistical differences in the distribution of continuous variables were analysed with the 
Mann-Whitney U-test. The Chi-Square test with continuity correction or Fischer’s exact test was 
used to compare the groups of the categorical data. The logistic regression model with forward 
selection was used in a multivariable analysis to test the risk factors. The survival time was 
estimated using the method of Kaplan and Meier. All statistics were performed with SPSS 
software for Windows 95. All p-values are two-tailed.  
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RESULTS 
 
Diagnostic findings (I, IV) 
 
Clinical features at diagnosis (I) 
 
Of the patients 97 were female and 73 male, with an F: M ratio of 1.3:1. The median age of the 
patients was 52 years (range 19-88 years). The peak incidence among females was in the age 
group of 40-49 years and among males in the age group of 60-69 years (Fig. 1). The females 
showed another less clear increase of incidence in the age group of over 70 years. 
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Figure 1. The age and sex distribution of the patients at the time of diagnosis. The grey and white 
bars represent females and males, respectively. 
 
Thrombocytosis was a chance finding in 65 % of the patients (n = 111), in 74 % of the females (n 
= 72) and in 53 % of the males (n = 39), while in 35 % of the patients (n = 59) symptoms were 
the reason for diagnostic evaluation. However, the past history of 37 "asymptomatic" patients 
revealed complications or symptoms which are known to be seen in ET. Thus, finally only 74 
patients (44 %) had no history of symptoms caused by ET. The females were significantly (p = 
0.002) more often asymptomatic at diagnosis than the males, and the difference was seen in all 
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age groups (< 40 years: 78 % vs. 56 %; 40-59 years: 78 % vs. 43 %; > 60 years: 74 % vs. 59 %, 
respectively). 
 
The complications at diagnosis are summarised in Table 7. Forty-eight patients (28 % of all 
patients and 50 % of those with complications or symptoms) had experienced altogether 70 
thrombotic complications, nearly half of which were major disturbances of the cerebral 
circulation. Three patients younger than 35 years of age had had an acute myocardial infarction. 
Thirty-nine patients (23 %) showed bleeding complications which caused only minor problems. 
Both thrombotic and haemorrhagic complications were detected in nine patients (5 %).  
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Table 7. The symptoms and complications of patients with ET at or preceding the diagnosis. The 
number of patients in whom the symptom or complication led to the diagnosis is given in 
parenthesis. The median and range of the platelet count (PLTx109/l) and the median age at the 
time of complication are shown. 
PLT  Age  
n1 Med Range Med Range 
----------------------------------------------------------------------------------------------------------------- 
No symptoms 74 929 500-2124 54 21-85 
Thrombosis 48 
Arterial: 43 
cerebral infarction 18 (16) 617 262-1800 51 24-79 
transient ischaemic attack 11 (9) 717 374-1100 53 32-69 
myocardial infarction /  
unstable angina pectoris 10 (6) 714 534-1288 47 27-85 
claudication 6   (4) 761 496-1000 59 34-88 
spontaneous abortion /  
stillborn baby 3 (3) 749 550-1320 32 24-38 
gangrene of toe 2 (0)    34-48 
bone infarction 1 (1)  788  41 
brachial artery embolism 1 (0)  582  46 
optic nerve ischaemia 1 (0)  694  80 
Venous: 7 
deep venous thrombosis 5 (4) 775 262-2000 52 29-75 
pulmonary embolism 2 (2)  262-425  29-50 
recurrent thrombophlebitis 1 (1)  733  28 
portal vein thrombosis 1 (1)  986  36 
Microvascular 36 
peripheral symptoms2 20 (10) 848 606-1729 51 39-88 
dizziness 10 (7) 806 620-1245 51 27-76 
visual disturbance 5 (1) 960 623-1547 47 45-53 
headache 4 (1) 607 507-1060 46 41-51 
migraine 2 (0)  620-1392  40-51 
grand mal epilepsy 1 (1)  675  58 
confusion 1 (1)  679  70 
Haemorrhages 39 
bruising 12 (3) 826 534-1340 47 32-72 
postoperative 11 (6) 810 520-2700 54 18-71 
gynecological 5 (0) 1024 743-1392 40 32-49 
gastrointestinal 4 (3) 927 776-1225 55 26-72 
wound bleeding 4 (0) 992 679-1320 46 38-63 
nasal 4 (1) 1004 679-1729 65 46-81 
gingival 3 (2) 794 728-1410 47 42-54 
haemoptysis 2 (1)  552-741  34-40 
urethral 2 (1)  622-844  67-73 
testicular 1 (1)  944  60 
----------------------------------------------------------------------------------------------------------------- 
1 = number of patients with the given symptom or complication 
2 = erythromelalgia, paraesthesia, Raynaud’s phenomenon, acral cyanosis 
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Laboratory and radiological findings (I) 
 
At the time of the diagnosis the median platelet count of the 170 patients was 885 x 109/l and the 
range 496-2175 x 109/l. The distribution of the platelet counts at diagnosis and the proportion of 
the patients with leukocytosis are shown in Table 8. In the bone marrow examination the most 
frequent abnormality was slight or moderate megakaryocytic hyperplasia, seen in 79 % of the 
aspirates and in 93 % of the biopsies (Table 8). In 80 % of the aspirates a variable number of 
large megakaryocytes with hyperlobulated nuclei were present. The bone marrow cellularity was 
normal in two thirds of the biopsies, and in 83 % of the evaluable aspirates it was estimated to be 
normal. In the rest of the biopsies and aspirates the cellularity was increased. Twenty-six per cent 
(32/121) of the patients examined either with ultrasound or tomography showed an enlarged 
spleen. The spleen was palpable in only five patients. Two patients had been splenectomized for 
diagnostic purposes six and 14 months before the diagnosis of ET, respectively. 
 
Table 8. The proportion of patients with abnormal findings at diagnosis. Total number of patients  
studied with the given test or examination is in parenthesis. 
 
 % of patients studied 
Platelets x 109/l (170) 
lower than 600 
600-999 
1000-1499 
more than 1500 
Leukocytosis > 10 x 109/l (170) 
Bone marrow aspirate / biopsy (154 / 31) 
increased cellularity 
increased number of megakaryocytes 
abnormal megakaryocyte morphology 
Splenomegaly (ultrasound or tomography) (121)
Abnormal platelet function (36) 
Karyotype abnormality (76) 
Spontaneous colony formation (134) 
 
 
4  
59  
29  
8 
32 
 
17 / 33 
79 / 93 
80 / 55 
26 
83 
5 
74 
 
 
Cultures of haematopoietic progenitors (I, IV) 
 
The erythroid (CFU-E and BFU-E) and megakaryocyte (CFU-Meg) progenitors of 154 patients 
were cultured in vitro by the methyl cellulose assay. At the time of the cultures 134 patients had a 
newly diagnosed disease, whereas 20 patients had had ET diagnosed 1-13 years before the 
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cultures. Either erythroid or megakaryocytic spontaneous colony formation was detected in 74 % 
of the patients (n = 114), whereas 26 % (n = 40) showed a normal growth pattern (Table 9). Of 
the patients 57 % (n = 88) had spontaneous erythroid colony formation and 59 % (n = 91) 
spontaneous megakaryocyte colony formation. Both megakaryocyte and erythroid spontaneous 
colony growth was shown by 42 % of the patients (n = 65). Spontaneous growth only in the 
megakaryocyte or erythroid cultures was seen in 17 % (n = 26) and 15 % (n = 23) of the patients, 
respectively. The presence of spontaneous colony formation was not statistically significantly 
different in the patients with blood progenitor cultures only when compared to the remaining 
patients.  
 
The platelet count at the time of the cultures had no effect on the growth pattern. The median 
platelet count was 843 x 109/l (range 464-2498 x 109/l) among the patients with spontaneous 
colony formation and 1014 x 109/l (range 531-1757 x 109/l) among those with normal colony 
growth. The presence of spontaneous colony formation was similar in the males (79 %) and the 
females (70 %).  
 
Table 9. Megakaryocytic and erythroid colony formation in 154 patients with ET. 
    
 
 
 
 
Spontaneous megakaryocytic 
colony formation 
 
 
 
 
 
Yes 
 
No 
 
Total 
 
Spontaneous erythroid 
 colony formation 
 
 
 
Yes 
No 
 
Total 
 
65 (42%) 
26 (17%) 
 
91 (59%) 
 
23 (15%) 
40 (26%) 
 
63 (41%) 
 
88 (57%) 
66 (43%) 
 
 
Platelet function (I, IV) 
 
The platelet function tests were performed in 36 patients at the time of the diagnosis or within a 
year after the diagnosis. Eighty-three per cent of them had defective aggregation. Of all 55 
patients investigated, 75 % (n = 41) showed abnormalities in the platelet function tests (Table 
10). The most common abnormality was defective aggregation induced by adrenaline (n = 32). 
No correlation was found between the platelet aggregation responses and the colony formation of 
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the haematopoietic progenitors (Table 10). Of the patients studied 51% (n = 28) showed defective 
platelet aggregation response with more than one inducing agent. The sex and age distribution of 
the patients with normal and abnormal platelet function was similar. 
 
Table 10. Platelet function tests in 55 patients with ET and the proportions of  
the patients with spontaneous colony formation. 
 
No. of patients Proportion with 
         n = 55 spontaneous growth 
____________________________________________________________ 
 
Normal aggregation  14 (25 %) 10 / 14 
Hypoaggregation  41 (75 %) 26 / 41 
adrenaline  32 
collagen  21 
ristocetin  16 
ADP  14 
arachidonate  2 
_____________________________________________________________ 
 
Cytogenetic features (I) 
 
At diagnosis conventional cytogenetic studies revealed an abnormal karyotype in four out of 76 
patients (5 %): 7q+; 3p-; 20q-,9+; and a structural abnormality in chromosome 16.  
 
 
Complications and transformation (I-IV, unpublished data) 
 
During the course of the disease, with the follow-up of 63 months, only 22 % of the 170 patients 
remained asymptomatic. Either at diagnosis or during the follow-up 76 patients (45 %), including 
five patients with a pregnancy loss, experienced altogether 144 thrombotic events. Only 20 % of 
all thrombotic complications were venous. Of the patients 21 % (n = 35) had a major bleeding 
complication. Either thrombosis or major bleeding occurred in 56 % of the patients (n = 95). Half 
of the patients had microvascular symptoms, the most common of which were disturbances of the 
peripheral circulation. Survival free from thrombosis and major bleedings is shown in Figure 2. 
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During the follow-up 24 patients (14 %) died. In 15 patients death was caused by thrombotic or 
haemorrhagic complications: cerebral infarction (n = 6), coronary artery disease or myocardial 
infarction (n = 4), pulmonary embolism (n = 4), and subdural bleeding (n = 1). The causes of 
death likely to be unrelated to ET included non-haematological malignancy (n = 3), pneumonia (n 
= 2), non-Hodgkin lymphoma (n = 1), aortic valve stenosis (n = 1), renal insufficiency (n = 1), 
and tetraplegy (n = 1). The probability of a ten-year survival was 90 % (Fig. 3). 
 
Transformation to MDS (refractory anaemia) occurred in one patient. The patient died of 
ventricular fibrillation within a year. No transformation to acute leukaemia occurred. Three 
patients transformed to myelofibrosis with collagen fibrosis of the marrow and 
leukoerythroblastic blood picture after four to six years of follow-up.  
 
Of the patients 6.5% (11/170) developed a constant erythrocytosis at the median of 29 months 
(range 12-138 months) after the diagnosis. The time from the discovery of thrombocytosis to the 
appearance of erythrocytosis ranged from 15 to 146 months (median 48 months). Despite 
erythrocytosis, in two patients the haemoglobin and haematocrit values remained within the 
normal range. In the other patients also the haemoglobin and haematocrit values exceeded the 
upper limit of the normal range. No significant differences could be found in the findings at 
diagnosis between the patients who later developed erythrocytosis and those who did not. The 
erythrocyte count, haemoglobin concentration, and haematocrit of the patients with later 
erythrocytosis were slightly, but not significantly, higher than those of the other patients. The 
cellularity and the proportion of erythropoiesis of the initial bone marrow aspirates as well as the 
presence of splenomegaly (14 % vs. 25 %, respectively) were similar in the patients with later 
erythrocytosis and in those with a stable disease. All ten patients with later erythrocytosis whose 
progenitors were cultured in the non-erythrocytic phase showed spontaneous erythroid colony 
formation compared to only 54 % of the patients with stable ET. Spontaneous megakaryocytic 
colony formation was seen in 80 % (8/10) of the patients with later erythrocytosis and in 57 % of 
those with a stable disease. The frequency of symptoms at diagnosis or after the development of 
erythrocytosis did not differ between the two groups. 
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Figure 2. Thrombosis-free and major bleeding-free survival of 170 patients with ET. 
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Figure 3. Overall survival of 170 patients with ET. 
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Prognostic factors for vascular complications 
 
Platelet count and age of the patients (I, III, IV, unpublished data) 
 
The risk of thrombotic or bleeding complications did not correlate with the platelet count. Of the 
thrombotic episodes 79 % occurred with a platelet count lower than 1000 x 109/l, 30 % with a 
platelet count lower than 600 x 109/l, and 14 % with a platelet count lower than 450 x 109/l. 
Similarly, the majority of the major bleedings (61 %) occurred with a platelet count lower than 
1000 x 109/l. 
 
The thrombotic complications did not correlate with age. One thrombotic complication or more 
were shown by approximately 30-40 % of the patients in each age group (Fig. 4). The risk of 
major bleedings was increased in the elderly patients. Twenty-eight per cent of the patients older 
than 60 years but only 14 % of the younger ones experienced a major bleeding episode (p = 0.03).  
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Figure 4. The proportion of the patients with thrombosis or major bleeding in the different age 
groups. The grey and white bars represent thrombotic and major bleeding complications, 
respectively. 
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Sex (I, III, IV) 
 
In multivariate analysis the male gender had a significant, independent prognostic impact on the 
risk of thrombotic complications, especially on the risk of arterial thrombosis. Of the males 58 % 
(36/62), whereas only 24 % (17/70) of the females, experienced arterial thrombosis (p = 0.0001). 
Males showed all types of arterial complications more frequently than females. No difference 
could be found in the incidence of venous thrombosis or bleeding complications between the 
genders.  
 
Cardiovascular risk factors (III) 
 
Sixty-three out of 132 patients (48 %) had one or more vascular risk factors, and 69 patients (52 
%) had no vascular risk factors (Table 11). Eleven per cent of the patients (n = 14) had several 
vascular risk factors. At diagnosis the patients without vascular risk factors had higher platelet 
counts (median 943 x 109/, range 496-2175 x 109/l) than those with risk factors (median 833 x 
109/, range 500-1757 x 109/l), (p = 0.04), but no difference in the peak platelet counts between the 
groups could be detected. The patients with one or more vascular risk factors were significantly 
older than those without risk factors (median age 58 vs. 46 years, respectively). The gender 
distribution and the proportion of the patients treated with platelet-lowering drugs or ASA did not 
differ between the groups. 
 
The presence of one or more vascular risk factors increased the risk of arterial thrombotic 
complications (Table 12). Approximately half of the patients (52 %) with at least one vascular 
risk factor, but only 29 % of those without risk factors, experienced arterial thrombosis (p = 
0.01). In multivariate analysis the only independent risk factor was smoking (p = 0.01); none of 
the remaining risk factors contributed significantly to arterial thrombotic complications (Table 
13). No significant difference in the age distribution between the smokers and non-smokers could 
be detected. The impact of smoking on the risk of complication was gender-dependent. Among 
females arterial complications occurred in 60 % (9/15) of the smokers but only in 15 % (12/82) of 
the non-smokers (p = 0.002), whereas among males no statistically significant difference was 
seen in arterial complications between smokers and non-smokers (Table 14). 
 
Cardiovascular risk factors did not predict the risk of venous thrombosis.  
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Table 11. Vascular risk factors in 132 patients with ET. 
 
No. of patients  Age (years)  Sex 
with risk factor  median range Female  Male 
_______________________________________________________________________ 
Smoking  32  53 24-79 15  17 
Hypertension  27  56 41-72 16  11 
Hypercholesterolaemia 21  59 41-79 12  9 
Diabetes mellitus 4  66 61-73 0  4 
 
One or more risk factors 63  58 24-79 33  30 
No risk factors  69  46 19-88 37  32 
_______________________________________________________________________ 
 
 
Table 12. Arterial thrombosis in relation to the risk factors in 132 patients with ET. 
Per cent of patients with thrombosis Risk factor No. of patients 
with risk factor 
Risk factor + Risk factor - P-value 
Smoking 
Hypertension 
Hypercholesterolaemia 
Diabetes mellitus 
One or more risk factors 
Male gender 
32 
27 
21 
4 
63 
62 
59% 
48% 
47% 
75% 
52% 
58% 
34% 
41% 
37% 
39% 
29% 
24% 
0.02 
ns 
ns 
ns 
0.01 
0.0001 
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Table 13. The significance of vascular risk factors and gender for the risk of arterial 
thrombosis. Multivariate analysis. 
 
 
Risk factor    p-value 
_________________________________________________ 
Smoking    0.01 
Hypertension    0.34 
Hypercholesterolaemia   0.45 
Diabetes mellitus   0.15 
Male gender    0.0001 
_________________________________________________ 
 
 
Table 14. The effect of smoking on arterial thrombotic complications according to gender. 
 
Arterial thrombosis  
smokers non-smokers p-value1) 
_________________________________________________ 
Males  10/17 (59%) 26/45 (58%) ns 
Females  9/15 (60%) 8/55 (15%) 0.002 
_________________________________________________ 
 
1) Fischer’s exact test    
 
In vitro colony formation of haematopoietic progenitors (IV) 
 
The presence of any spontaneous colony formation increased the risk of arterial thrombosis 
markedly (Table 15). Forty-three per cent of the patients (49/114) with spontaneous colony 
formation (megakaryocytic and/or erythroid), but only 20 % (8/40) without it, had an arterial 
thrombosis (p = 0.02). Spontaneous colony formation was also more often seen in patients with 
an arterial thrombotic complication at diagnosis than in those without thrombosis at diagnosis (all 
patients p = 0.01, patients younger than 45 years p = 0.04). In the patients younger than 45 years 
spontaneous megakaryocytic growth alone had prognostic value: 44 % of the patients (15/34) 
with spontaneous megakaryocytic colony growth and 14 % (3/21) of those without spontaneous 
colony formation experienced an arterial thrombotic complication during the course of the 
disease (p = 0.04) (Table 15). When all patients were included, erythroid or megakaryocytic 
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colony formation did not predict arterial thrombosis. In multivariate analysis of all patients the 
male gender (p = 0.001, 95 % CI 1.75-7.37) and any spontaneous colony formation (p = 0.009, 
95% CI 1.40-10.30) remained as independent risk factors for arterial thrombosis. In the patients 
younger than 45 years also spontaneous megakaryocytic colony formation (p = 0.04) remained as 
an independent risk factor. Spontaneous colony growth did not predict the risk of venous 
thrombosis or bleeding complications. 
 
Table 15. The correlation between spontaneous colony formation and the risk of arterial 
thrombosis in all patients (n = 154) and patients younger than 45 years of age (n = 55). 
 
 
 
 
Number of patients  
with arterial thrombosis / total (% with complication) 
 
Growth pattern 
 
All patients 
 
p 
 
< 45 years 
 
p 
 
Any spontaneous colony growth 
Normal colony growth 
 
Spontaneous CFU-Meg growth 
Normal CFU-Meg growth 
 
Spontaneous BFU-E growth 
Normal BFU-E growth 
 
49 / 114 (43 %) 
 8 / 40 (20 %) 
 
38 / 91 (44 %) 
19 / 63 (30 %) 
 
38 / 88 (43 %) 
19 / 66 (29 %) 
 
 
0.02 
 
 
0.19 
 
 
0.09 
 
18 / 46 (39 %) 
0 / 9 (0 %) 
 
15 / 34 (44 %) 
3 / 21 (14 %) 
 
13 / 36 (36 %) 
5 / 19 (26 %) 
 
 
0.04 
 
 
0.04 
 
 
0.67 
 
Platelet function (IV) 
 
Abnormal platelet aggregation did not correlate significantly with the risk of thrombotic or 
bleeding complications. However, there was a trend towards fewer complications among the 
patients with abnormal platelet aggregation. Arterial thrombosis was seen in 43 % of the patients 
with sufficient platelet aggregation and in 24 % of the patients with defective platelet aggregation 
(p = 0.33). The corresponding figures for venous thrombosis and major bleedings were 21 % vs. 
7 % (p = 0.33) and 36 % vs. 12 % (p = 0.12), respectively. 
 
Normal colony formation and abnormal platelet aggregation response showed each a trend 
towards a decreased risk of arterial thrombotic complications. Only 6 % (1/15) of the patients 
with both of these favourable findings experienced an arterial thrombosis, while 38 % (15/40) of 
the remaining patients had arterial complications (p = 0.04).  
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Outcome of pregnancy in ET (V) 
 
Eighteen of the 40 pregnancies (45 %) of 16 females were complicated. Fifteen pregnancies (38 
%) ended in miscarriage; 13 of these occurred during the first trimester comprising 87 % of all 
miscarriages. Three pregnancies ending in live birth were complicated by eclampsia or pre-
eclampsia. Altogether 25 pregnancies (62 %) resulted in live birth of 26 newborns. The clinical 
course of pregnancy was uneventful in all 11 pregnancies of seven women. In the remaining nine 
patients 18/29 (62 %) pregnancies were complicated. Five females had more than one 
complicated pregnancy.  
 
Three out of 26 placentas appeared clinically abnormal. In two pregnancies leading to a stillbirth 
the placentas showed calcification and multiple infarcts, while one pregnancy with large areas of 
placental infarctions resulted in a preterm delivery of a small-for-date infant.  
 
The foetal growth was within normal limits in 24 of the 25 pregnancies resulting in live birth with 
the median length of gestation of 39 weeks. No abnormal bleedings during the delivery were 
reported. The median birth weight was 3190 g (range 500-4540 g). The platelet count was 
analysed in 12 newborns (median 284 x 109/l, range 192-540 x 109/l), and in five of them the 
platelet count was above the normal limit (> 290 x 109/l). 
 
The platelet count before the conception or during the first trimester did not correlate with the 
outcome of the pregnancy. The median platelet count in 16 pregnancies resulting in live birth was 
757 x 109/l and in 13 pregnancies ending in pregnancy loss 835 x 109/l. Other ET-related 
symptoms prior to or during the pregnancy were not found to predict the appearance of 
pregnancy complications. 
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Impact of treatment for ET on the course of pregnancy 
 
Treatment for ET was or had been given to 11 of the 16 females (67 %) in connection with 13 
pregnancies, either during the pregnancy or before conception or both. ASA was given in 
altogether ten pregnancies of nine patients in daily doses ranging from 50 to 250 mg. Two of 
these patients were already on ASA treatment before the conception and continued with it 
throughout the pregnancy. In the other seven patients the treatment was started at 4 - 27 weeks of 
gestation, in four of them during the first trimester. Five patients were on IFN treatment. Three of 
them discontinued IFN after conception and switched over to ASA, one patient continued with 
IFN from week 15 onwards after an eight-week break, and one patient continued with the IFN 
treatment throughout the pregnancy. Both patients on IFN treatment during the pregnancy also 
received concomitantly ASA. Two females with three pregnancies had been treated with 
busulphan two months and 26 months before conception. 
 
Pregnancy-related complications occurred in 18 of the 27 pregnancies (67 %) in females without 
any treatment, whereas none of the 13 pregnancies in females with treatment before or during the 
pregnancy were complicated (p < 0.001). The live-birth rate in the treated patients (13/13 
pregnancies, 100 %) was higher than that in the untreated patients (12/27 pregnancies, 44 %) (p < 
0.001) (Table 16). Eight out of eight pregnancies (100 %) with ASA alone versus 12 out of 27 
pregnancies (44 %) without any treatment resulted in live birth (p = 0.01). 
 
Table 16. The impact of treatment on the pregnancy outcome.  
  
  
 
 
 
Live birth 
 
Miscarriage 
 
No treatment 
 
12 
 
15 
 
ASA alone 
 
8 
 
0 
 
Platelet lowering treatment + ASA 
 
5 
 
0 
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DISCUSSION 
 
For clinicians ET is still both a diagnostic and therapeutic challenge. Of the MPDs the prognosis 
of ET is the most favourable. It is generally agreed that the life expectation of patients with ET 
does not markedly differ from that of the age- and sex-matched control population. At the time of 
the diagnosis patients are often young and symptomless and, due to the wide use of automatic cell 
counters, thrombocytosis is often a chance finding. According to previous studies, many patients 
are symptomless for years, but there is a danger of life-threatening and serious complications 
mostly caused by arterial thrombosis and less often by venous thrombosis or bleedings. The 
diagnosis of ET as such is not an indication for treatment, and the indications are still 
controversial. Most previous studies dealing with risk factors have been published in countries, 
such as those in southern Europe, where the cardiovascular morbidity among the population is 
generally lower than in Finland. Thus the risk of complications in Finnish ET patients may be 
different from that in some other populations. The aim of the present study was to describe the 
diagnostic and prognostic features as well as the outcome of Finnish patients with ET. 
 
Diagnosis of ET 
 
The goal of the diagnosis of thrombocytosis is to distinguish ET from other MPDs and RT. The 
differential diagnosis of ET from the other MPDs is usually relatively straightforward and based 
on adequate iron stores, normal red cell count, as well as on the lack of collagen fibrosis and 
karyotype abnormalities typical of CML. Difficulties usually appear in the differential diagnosis 
between ET and RT. Reliable diagnostic methods would be of importance, since RT hardly ever 
causes problems and complications which the patients with ET are prone to. In addition, the 
platelet lowering treatments used in ET carry a potential of severe side-effects. Therefore positive 
diagnostic criteria and the evaluation of diagnostic tools are needed. 
 
In the 1980’s the PVSG has proposed widely used diagnostic criteria for ET (Murphy et al. 
1986). Although the diagnosis of the patients in the present study has been based on the criteria 
of PVSG with some modifications, this classification has considerable, well-known limitations. 
The diagnosis of ET is based on the exclusion of other causes of thrombocytosis, and the lower 
limit of the platelet count justifying the diagnosis of ET, 600 x 109/l, is too high. Previous studies, 
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as well as the present one, show that patients may experience thrombotic complications with 
platelet counts only slightly above (Hehlmann et al. 1988, Regev et al. 1997, Lengfelder et al. 
1998), or even within, the normal range. A recent proposal for revised diagnostic criteria for ET 
has defined the platelet count of 400 x 109/l as the lower diagnostic limit (Michiels and Juvonen 
1997). In addition, during the recent years new diagnostic tools have been proposed and their 
impact is not yet well defined. Positive criteria that might support the diagnosis of ET are bone 
marrow morphology (Michiels and Thiele 2002, Thiele and Kvasnicka 2005), enlarged spleen, 
karyotype abnormalities, platelet volume and distribution width, platelet nucleotide ratio (Dudley 
et al. 1989), abnormal platelet function studies (Sehayek et al. 1988, Zahavi et al. 1991), 
spontaneous colony formation in in vitro cultures of haematopoietic progenitors (Juvonen et al. 
1993, Kutti and Wadenvik 1996, Westwood and Pearson 1996, Michiels and Juvonen 1997), and 
JAK2 mutation (Campbell and Green 2005, Tefferi and Gilliland 2005). 
 
The WHO citeria (Imbert et al. 2001) emphasize histological findings of the bone marrow biopsy, 
and histology has been proposed as a tool to establish the diagnosis of ET. Clustering of enlarged 
megakaryocytes with multilobulated nuclei is a common finding in ET, as also shown in the 
present study. It has even been proposed that bone marrow biopsy could facilitate an earlier 
diagnosis in patients with only moderately elevated platelet counts (400 – 600 x 109/l) 
(Lengfelder et al. 1998, Sacchi et al. 2000). The evaluation of bone marrow morphology has been 
proposed as a predictor of a disease subtype, indicating that “true ET” may be distinguished form 
early myelofibrosis or latent PV (Thiele et al. 2000, Thiele and Kvasnicka 2005). The prognostic 
significance of bone marrow findings has been shown in one study (Annaloro et al. 1999). The 
diagnostic classification based on bone marrow histology is, however, limited by the fact that 
megakaryocyte morphology and reticulin grading are difficult to assess in a reproducible manner 
(Harrison 2005b).  
 
The presence of spontaneous colony formation of haematopoietic progenitors has been included 
as a positive marker in the less well known European Clinical and Pathological criteria (Michiels 
and Juvonen 1997), but not in the PVSG or WHO criteria. In the three largest studies, 63-100 % 
of the patients with ET have shown spontaneous megakaryocytic colony formation and 59-88 % 
spontaneous erythroid colony formation (Juvonen et al. 1993, Florensa et al. 1995, Rolovic et al. 
1995). Our study confirmed the findings of a previous study of the present authors with a smaller 
patient group (Juvonen et al. 1993) that either megakaryocytic or erythroid spontaneous colony 
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formation is seen in the majority (74 %) of the ET patients. The majority of the patients in the 
present study also showed deficient platelet aggregation (75 %). Of the 55 patients tested for both 
colony formation and platelet aggregation 51 had abnormal results in both or at least one of these 
tests. It is therefore obvious that abnormal in vitro cultures and platelet function studies support 
the diagnosis of MPD. These tests are, however, technically demanding, difficult to standardize, 
and available only in relatively few haematological laboratories. The differential diagnostic 
usefulness of platelet function studies may be limited by an overlap between myeloproliferative 
and reactive thrombocytosis, as seen in some previous studies (Sehayek et al. 1988, Majer et al. 
1991).  
 
The over-expression of the PRV-1 gene, which has been a molecular marker in PV, can be 
detected in approximately half of the patients with ET. However, as a diagnostic tool it has turned 
out to be a disappointment, because the PRV-1 over-expression is constitutively detectable in 
bone marrow cells and it does not differentiate PV or ET from reactive disorders or from other 
MPDs (Bock et al. 2003, Tefferi et al. 2003, Passamonti et al. 2004a). It is obvious that in the 
future the JAK2V617F mutation screening will be included in the diagnostic algoritm (Campbell 
and Green 2005, Tefferi and Gilliland 2005), as it offers a diagnostic tool for a MPD in half of 
the ET patients. The precise role of the JAK2 mutation remains to be seen. The present studies 
were performed before the JAK2 era, and the JAK2 mutation data is not available. Thus, the 
relationship between the JAK2 mutational status and the classical diagnostic findings in ET could 
not be evaluated.  
 
The proportion of our patients whose diagnosis was made by chance was higher than that in 
several earlier studies (Hehlmann et al. 1988, Cortelazzo et al. 1990, Fenaux et al. 1990, Randi et 
al. 1991, van Genderen et al. 1997a, Lengfelder et al. 1998). It was interesting that in all age 
groups the disease was diagnosed in a significantly higher proportion of females by chance, and 
the peak incidence of the disease among the female patients was two decades earlier than that in 
the males (40-50 years vs. 60-70 years, respectively). The active use of health care services by 
females in general together with systematic maternity care may at least partly explain the 
differences in the distribution of age and symptoms between the sexes, and the high incidence of 
atherosclerosis in the Finnish male population (Uemura and Pisa 1988) may contribute to these 
findings. 
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Thrombohaemorrhagic complications and prognostic factors 
 
The precise incidence of thrombohaemorrhagic complications in ET is difficult to ascertain, since 
most studies are retrospective by nature, event definitions and result reporting vary, and there 
may have been a bias with the patient selection. In previous large studies the incidence of major 
thrombotic complications at the diagnosis of ET has varied from 11 to 25 % and during follow-up 
from 10 to 23 % (Bellucci et al. 1986, Cortelazzo et al. 1990, Fenaux et al. 1990, Colombi et al. 
1991, Besses et al. 1999, Jensen et al. 2000a). In the study of Bazzan et al. (1999) with 187 
patients the incidence of thrombotic complications during the follow-up of nine years was as high 
as 50 %, but the patients were originally selected to the special thrombosis unit due to a 
thrombotic event causing a bias towards a high-risk patient population. In the prospective trial 
with hydroxyurea (Cortelazzo et al. 1995, Finazzi et al. 2000) the total incidence of thrombosis in 
the control group comprising high-risk patients was 45 %, while in a prospective study with low-
risk patients the incidence was only 7.7 % (Ruggeri et al. 1998). The total rate of thrombotic 
complications (45 %), especially arterial events, was clearly higher in the Finnish patients with 
ET than in most of the previous retrospective studies (Bellucci et al. 1986, Chistolini et al. 1990, 
Cortelazzo et al. 1990, Fenaux et al. 1990, Colombi et al. 1991, van Genderen et al. 1997a, 
Besses et al. 1999, Jensen et al. 2000a). This may reflect the relatively high incidence of 
cardiovascular problems in the Finnish population in general (Uemura and Pisa 1988). Indeed, 
half of our patients had at least one cardiovascular risk factor. The patients of the present study 
were referred to the participating municipal or central hospitals directly from the primary health 
care centers, indicating that this patient population may be considered the least selected among 
the published reports, without any obvious selection bias. Contrary to thrombotic complications, 
the incidence of bleedings in the present patients was in line with that of the previous reports. The 
incidence of major bleeding rates varied from 3.6 to 37 % in the previous studies (Bellucci et al. 
1986, Cortelazzo et al. 1990, Fenaux et al. 1990, Colombi et al. 1991, Besses et al. 1999, Jensen 
et al. 2000a) being 21 % in our study. 
 
In the present study the platelet count did not predict thrombotic or bleeding complications, 
which is in agreement with most of the previous studies as regards to thrombosis (Cortelazzo et 
al. 1990, Colombi et al. 1991, Bazzan et al. 1999, Besses et al. 1999), but not with the studies 
showing an increased frequency of bleeding complications at high platelet counts (Bellucci et al. 
1986, Fenaux et al. 1990). Age has been associated with an increased risk of thrombosis in four 
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reports (Cortelazzo et al. 1990, Randi et al. 1992, Besses et al. 1999, Shih et al. 2002). However, 
in the present study the incidence of thrombotic complications was similar in all age groups, and 
serious complications occurred also in young and middle-aged patients. The present finding of a 
higher incidence of major bleedings in older patients has been previously described once (Shih et 
al. 2002) and it may be associated with the presence of other illnessess and treatments, but no 
correlation to the use of ASA could be detected.  
 
Previous reports of the influence of cardiovascular risk factors, such as smoking, hypertension, 
hypercholesterolaemia, and diabetes, on thrombotic complications in ET have been conflicting. 
In a retrospective study with 148 ET patients hypercholesterolaemia alone was shown to be an 
independent risk factor (Besses et al. 1999). Watson and Key (1993) reported a study of 46 
patients with a follow-up of 50 months, in which vascular risk factors, especially smoking, more 
than doubled the risk of complications. In the prospective study of Ruggeri et al. (1998) of 65 
low-risk ET patients aged less than 60 years, obesity, but no other cardiovascular risk factors, 
predicted the risk of thrombosis. However, other large studies failed to reveal these associations 
(Hehlmann et al. 1988, Cortelazzo et al. 1990, Fenaux et al. 1990, van Genderen et al. 1997b, 
Bazzan et al. 1999, Jensen et al. 2000a). In the present study the median follow-up was long, 
more than five years, and particularly the results of the predictive value of smoking are in line 
with those in the study of Watson and Key (1993) with a long follow-up. Smoking favours 
thrombosis by impairing the endothelial cell function, increasing the concentrations of fibrinogen 
and vascular cell adhesion molecule-1, altering platelet activation, and decreasing the 
concentration of high-density lipoprotein cholesterol (Garrison et al. 1978, Reinders et al. 1986, 
Nowak et al. 1987, FitzGerald et al. 1988, Celermajer et al. 1993, Celermajer et al. 1994, Casey 
et al. 2004, Cavusoglu et al. 2004). The observation that smoking had a strong predictive value 
for the development of arterial thrombotic complications in females, whereas there was no 
correlation between smoking and arterial complications in males, is intriguing. Hormonal 
differences between the sexes may explain this finding to some extent. Estrogen can prevent 
cardiovascular complications by several mechanisms, including an increase in the endothelium-
dependent vasodilatation and basal arterial diameter and a decrease in the basal vascular 
resistance, leading to an improvement of the endothelial function (Celermajer et al. 1993, 
Lieberman et al. 1994, Reis et al. 1994). Estrogen therapy has also been shown to lower LDL 
cholesterol and raise HDL cholesterol, which improves endothelial function (Miller et al. 1995). 
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The present finding showing no difference in the arterial thrombotic complications between 
smoking and non-smoking males remains unexplained. 
 
Knowledge of the prognostic value of spontaneous in vitro colony formation of haematopoietic 
progenitors is limited. In the previous studies with smaller patient populations erythroid 
spontaneous colony formation did not predict thrombotic complications (Ciaudo et al. 1998, 
Chiusolo et al. 2001), which is in accordance with the present larger study. The correlation 
between megakaryocytic spontaneous colony formation and an increased risk of 
thrombohaemorrhagic complications was already shown in a previous study of 61 patients by the 
present authors (Juvonen et al. 1993). The present study confirmed this finding in younger 
patients. The prognostic difference between the megakaryocytic or erythroid colony formation is 
not clear but it may be only a matter of sample size. In the present study the patients with 
spontaneous erythroid colony formation showed a trend toward an increased risk of arterial 
thrombotic complications, though the difference did not reach statistical significance. 
 
Transformation 
 
Myeloproliferative disorders can transform into another disease of the same group, a 
myelodysplastic syndrome or acute myeloid leukaemia. The rate of fibrotic transformation in the 
present study was low corresponding to previous large studies (Bellucci et al. 1986, Fenaux et al. 
1990, Cervantes et al. 2002). The evolution of ET to PV has previously been described 
infrequently. In the present study the development of erythrocytosis in 6.5 % of the patients with 
typical ET was rather unexpected and reflects the close relationship between these disorders. 
Spontaneous erythroid colony formation was seen in all patients who later developed 
erythrocytosis but only in 60 % of those with stable ET. Thus, spontaneous erythroid colony 
formation is not predictive of the development of erythrocytosis in individual patients with newly 
diagnosed ET, but normal erythroid colony growth may indicate a stable ET. 
 
The rate of myelodysplastic or leukaemic transformation was low (one out of 170 patients), 
which confirms the opinion that leukaemic transformation is sporadic in untreated patients 
(Barbui 2004a). The present patient who developed myelodysplastic transformation had earlier 
been treated with radiophosphorus. None of the patients receiving hydroxyurea showed 
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leukaemic transformation, but the median follow-up time of five years is relatively short for 
leukaemic transformation. 
 
Outcome and management of pregnancy 
 
Up till now the published number of pregnancies in patients with ET is limited, and most reports 
include a small number of patients which may cause a selection bias toward complicated cases. 
Only a few large reports are, so far, available (Beressi et al. 1995, Cincotta et al. 2000, Wright 
and Tefferi 2001). The high rate of miscarriages in the present study is contrary to several reports 
with successful pregnancy outcomes (Jones et al. 1988, Linares et al. 1988, Beard et al. 1991, 
Chow et al. 1992, Randi et al. 1994, Randi et al. 2000), but in line with the miscarriage rate of 33-
40 % in some previous studies (Pagliaro et al. 1996, Bangerter et al. 2000, Cincotta et al. 2000). 
In the largest report from the Mayo Clinic the rate of miscarriages was as high as 49 % and the 
rate of the first-trimester abortions 37 % (Wright and Tefferi 2001). The miscarriage rate in ET is 
clearly higher than that of 12-15 % in the normal population (Houwert-de Jong et al. 1989, 
Cramer and Wise 2000). 
 
The prediction of the pregnancy-related complications is difficult, as shown in the present study. 
Neither the platelet count prior to or during the pregnancy nor ET-related symptoms correlate 
with the pregnancy outcome. In our patient population five out of nine patients with a previous 
pregnancy complication also had problems during the following pregnancies. Thus, a 
complication in a previous pregnancy seems to be associated with a tendency to a new 
complication in the subsequent pregnancies.  
 
The precise pathophysiology of pregnancy complications in ET remains unclear. It has been 
suggested that normal physiologic changes in pregnancy favouring thrombosis are exacerbated 
when some other thrombophilic disorder is present. In normal pregnancy increased platelet 
activation and increased production of TXA2 are present (Fizgerald et al. 1987). In ET placental 
insufficiency obviously plays a key role in pregnancy complications (Harrison 2005 a). Several 
cases of placental thrombosis leading to intrauterine foetal death have been described in the 
literature (Falconer et al. 1987, Mercer et al. 1988). There may be a direct placental damage, or a 
shift of prostaglandin/thromboxane ratio may lead to a decreased placental perfusion. Excessive 
TXA2 biosynthesis has been described in ET (Zahavi et al. 1991, Rocca et al. 1995). ASA inhibits 
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TXA2 and shifts the balance of prostaglandin and thromboxane to antiaggregation, which 
provides a rational basis for the treatment with ASA during pregnancy in patients with ET. In a 
recent literature review the live birth ratio among the patients treated with ASA alone or in 
combination was 68 % but in the untreated patients only 48 % (Griesshammer et al. 2003). The 
use of ASA was advantageous in some previous studies (Bangerter et al. 2000, Cincotta et al. 
2000, Randi et al. 2000) as well as in the present study, but the largest reports from the Mayo 
Clinic have failed to reveal the benefit of the ASA treatment (Beressi et al. 1995, Wright and 
Tefferi 2001).  
 
The management issues of ET– whom and how to treat? 
 
All patients with a history of a thrombohaemorrhagic complication or aged higher than 60 years 
are regarded as high-risk patients, and platelet lowering treatment is indicated in these patients 
(Cortelazzo et al. 1995). Finnish male patients may be regarded as high-risk patients and therefore 
platelet lowering treatment should also be actively considered in them. A high platelet count of 
1000–1500 x 109/l indicates platelet lowering treatment due to an increased risk of bleeding 
complications (Barbui et al. 2004b, Finazzi and Harrison 2005). Smoking should be discouraged 
and stopped when the diagnosis of ET is established. In young patients the presence of 
spontaneous megakaryocyte colony formation may indicate a need of therapy. On the other hand, 
non-smoking female patients and young patients without any spontaneous megakaryocyte colony 
formation may be observed without therapeutic interventions.  
 
Some previous reports (Regev et al. 1997, Storen and Tefferi 2001) as well as the present study 
suggest that if platelet lowering treatment is indicated, the platelet count should be brought back 
to the normal levels (< 400 x 109/l). In younger patients IFN is an effective and safe alternative, 
but its use is limited by several side-effects. As a single agent hydroxyurea obviously carries only 
a minimal leukaemogenic risk and is therefore useful in patients not tolerating IFN. In elderly 
patients (> 70 years) radioactive phosphorus and busulphan are alternative treatments. In the 
PT1-study, which compared anagrelide and ASA with hydroxyurea and ASA, arterial thrombosis, 
major bleeding, and myelofibrosis were significantly more frequent in patients treated with 
anagrelide (Harrison et al. 2005). Thus, the role of anagrelide needs further evaluation.  
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The efficacy of ASA in the primary prevention of thrombotic complications has recently been 
shown in PV (Landolfi et al. 2004). Due to the generally increased thromboxane biosynthesis in 
MPDs, it may be assumed that also patients with ET benefit from low-dose ASA as primary 
prevention of thrombotic complications; therefore the use of low-dose ASA may be indicated in 
all ET patients. Among patients with any contraindications to ASA, such as a history of bleeding 
or high platelet counts (> 1000–1500 x 109/l), the need for platelet lowering treatment should be 
considered. Practical suggestions for the management of ET are presented in Table 17. 
 
In pregnancies of ET patients it seems reasonable to give low-dose ASA since the early weeks of 
pregnancy or since the pregnancy is being planned. If the patient has a contraindication to ASA 
and she has experienced a thrombohaemorrhagic complication during her previous pregnancy, 
platelet lowering treatment with IFN is indicated.  
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Table 17. Practical suggestions for the management of patients with ET based on the present 
findings and on the literature. 
 
Proposed management Risk category 
ASA Platelet lowering 
treatment 
Low / intermediate risk 
 
All of the following: 
Platelet count < 1000–1500 x 109/l1 
Age < 60 years1,2 
Female gender2 
No symptoms1 
No cardiovascular risk factor(s)1,2 
+ / - 
 
 
- 
 
 
High risk 
 
Any of the following: 
Male gender2 
Platelet count > 1000–1500 x 109/l1 
Age > 60 years1,2  
Symptoms1 
Prior thrombosis1 
Prior haemorrhage1 
Cardiovascular risk factor(s)1,2 
 
 
 
 
+ 
- 
+ 
+ 
+ 
- 
+ 
 
 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
1literature 
2present findings 
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SUMMARY AND CONCLUSIONS  
 
The aims of the present study were to evaluate the diagnostic findings, clinical course, and 
prognostic factors of essential thrombocythaemia in 170 Finnish patients with ET diagnosed and 
followed during the years 1980-1995. 
 
At the time of the diagnosis the median age of the patients was 52 years with a wide range from 
19 to 88 years. One third of the patients were younger than 45 years. There was a slight excess of 
female patients with an F : M ratio of 1.3 : 1. The peak incidence in females was two decades 
earlier than in males (40-49 years vs. 60-69 years, respectively). In the majority of the patients 
ET was diagnosed by chance, and females were more frequently asymptomatic at the time of the 
diagnosis than males. In the symptomatic patients the most frequent cause for diagnostic 
evaluations was a thrombotic complication. Of the thrombotic complications nearly half were 
major disturbances of the cerebral circulation. About two thirds of the patients presented with a 
platelet count of < 1000 x 109/l. The most common positive findings supporting the diagnosis of 
ET, in addition to conventional criteria, were an increased number of megakaryocytes with 
abnormal morphology in a bone marrow aspirate, platelet aggregation defects in the platelet 
function studies, and the presence of spontaneous erythroid and/or megakaryocytic colony 
formation in the in vitro cultures of haematopoietic progenitors. Approximately 70 % of the 
patients had either spontaneous megakaryocytic or erythroid colony formation, while about 30 % 
of the patients showed a normal haematopoietic progenitor growth pattern.  
 
At diagnosis or during the course of the disease only about 20 % of the patients remained 
asymptomatic. Approximately half of the patients experienced a major thrombohaemorrhagic 
complication. Thrombotic complications were more frequent than bleedings (45 % of the 
patients). Microvascular symptoms were experienced by half of the patients. About 20 % of the 
patients had major bleeding complications.  
 
Transformation to myelofibrosis was a rare event in the present ET patients, but 6.5 % of the 
patients developed erythrocytosis during the follow-up. No leukaemic transformation occurred.  
 
  66
The proportion of the patients with arterial thrombotic events was higher in the Finnish patients 
compared to the findings of most reports dealing with other populations. The platelet count did 
not predict thrombotic or bleeding complications. Age over 60 years increased the risk of major 
bleedings, but, in the present Finnish patients the occurrence of thrombotic complications was 
similar in all age groups, unlike in some other reports. This study showed, for the first time, male 
gender as a risk factor for thrombosis in ET. Smoking, especially in females, correlated with a 
risk of thrombosis. The presence of any spontaneous colony formation increased the risk of 
arterial thrombosis in all patients, while in young patients also spontaneous megakaryocytic 
colony formation had predictive value. 
 
Pregnancies in patients with ET carried an increased risk of complications. Eighteen out of 40 
pregnancies (45 %) were complicated. Fifteen pregnancies (38 %) resulted in stillbirth, most of 
them during the first trimester. A complication during a previous pregnancy predicted problems 
also during subsequent pregnancies. Contrary to a previous large report, treatment with ASA 
alone or in combination with platelet lowering drugs significantly improved the outcome of the 
pregnancy in the present retrospective analysis. 
 
Conclusions 
 
The main findings of the present study were the following: Spontaneous colony formation in the 
in vitro cultures of haematopoietic progenitors supported the diagnosis in a considerable 
proportion of the patients with ET. The presence of any spontaneous colony formation in all 
patients and the presence of spontaneous megakaryocytic colony growth in the patients younger 
than 45 years had also prognostic value. Male gender and smoking in female patients increased 
the risk of thrombotic complications. The occurrence of thrombotic complications in females was 
less frequent than in males, but the risk of pregnancy complications was considerable. 
 
The conclusions of the treatments and their effects are limited due to the retrospective nature of 
the study, heterogeneous treatments, and the long period covered, but some clearly suggestive 
observations were made, including the benefit of ASA particularly during pregnancies.  
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In the future the present findings of risk factors in ET as well as treatment outcome in the 
pregnancies of ET patients should be taken into consideration when planning treatment strategies 
for Finnish patients, including the indications for low-dose ASA or platelet lowering drugs and 
the importance of effective interventions to other cardiovascular risk factors. 
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